

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

**CUMULATIVE
SUPPLEMENT 2
FEBRUARY 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 2

February 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 2
February 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate

for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBVIE	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active

ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEPT 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED	17151				
SINGLE SOURCE	2664 (15.5%)				
MULTISOURCE	14487 (84.5%)				
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)				
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)				
EXCEPTIONS ¹	73 (0.4%)				
NEW MOLECULAR ENTITIES APPROVED	28				
NUMBER OF APPLICANTS	1011				

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will

display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
 >D> CAMPRAL
 >D> AB + FOREST LABS 333MG N021431 001 Jul 29, 2004 Feb DISC
 >A> @ 333MG N021431 001 Jul 29, 2004 Feb DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 @ INGENUS PHARMS NJ 325MG;50MG;40MG A040864 001 Dec 01, 2008 Jan CAHN
 @ SUN PHARM INDS 325MG;50MG;40MG A040601 001 Jul 29, 2005 Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
 OXYCODONE AND ACETAMINOPHEN
 >A> AA ALVOGEN MALTA 325MG;5MG A202677 003 Mar 08, 2016 Feb NEWA
 AA 325MG;7.5MG A202677 001 Jul 26, 2012 Jan CAHN
 AA 325MG;10MG A202677 002 Jul 26, 2012 Jan CAHN
 >D> AA COASTAL PHARMS 325MG;2.5MG A090177 001 Oct 20, 2008 Feb CAHN
 >D> AA 325MG;5MG A090177 002 Oct 20, 2008 Feb CAHN
 >D> AA 325MG;7.5MG A090177 003 Oct 20, 2008 Feb CAHN
 >D> AA 325MG;10MG A090177 004 Oct 20, 2008 Feb CAHN
 >D> @ 500MG;7.5MG A090177 005 Oct 20, 2008 Feb CAHN
 >D> @ 650MG;10MG A090177 006 Oct 20, 2008 Feb CAHN
 >A> AA MAYNE PHARMA INC 325MG;2.5MG A090177 001 Oct 20, 2008 Feb CAHN
 >A> AA 325MG;5MG A090177 002 Oct 20, 2008 Feb CAHN
 >A> AA 325MG;7.5MG A090177 003 Oct 20, 2008 Feb CAHN
 >A> AA 325MG;10MG A090177 004 Oct 20, 2008 Feb CAHN
 >A> @ 500MG;7.5MG A090177 005 Oct 20, 2008 Feb CAHN
 >A> @ 650MG;10MG A090177 006 Oct 20, 2008 Feb CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
 ACETYLCYSTEINE
 >A> AP AUROBINDO PHARMA LTD 6GM/30ML (200MG/ML) A207358 001 Feb 29, 2016 Feb NEWA
 TABLET, EFFERVESCENT;ORAL
 CETYLEV
 ARBOR PHARMS LLC 500MG N207916 001 Jan 29, 2016 Jan NEWA
 + 2.5GM N207916 002 Jan 29, 2016 Jan NEWA

ACYCLOVIR

CAPSULE;ORAL
 ACYCLOVIR
 >D> AB RANBAXY 200MG A074975 001 Sep 30, 1998 Feb DISC
 >A> @ 200MG A074975 001 Sep 30, 1998 Feb DISC
 TABLET;BUCCAL
 SITAVIG
 + CIPHER PHARMS US 50MG N203791 001 Apr 12, 2013 Jan CAHN
 TABLET;ORAL
 ACYCLOVIR
 >D> AB SUN PHARM INDS LTD 400MG A074980 001 Sep 30, 1998 Feb DISC
 >A> @ 400MG A074980 001 Sep 30, 1998 Feb DISC
 >D> AB 800MG A074980 002 Sep 30, 1998 Feb DISC
 >A> @ 800MG A074980 002 Sep 30, 1998 Feb DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION
 ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
 >D> + HIKMA MAPLE EQ 500MG BASE/VIAL A074885 001 Dec 19, 1997 Feb DISC
 >A> @ EQ 500MG BASE/VIAL A074885 001 Dec 19, 1997 Feb DISC
 >D> EQ 1GM BASE/VIAL A074885 002 Dec 19, 1997 Feb DISC
 >A> @ EQ 1GM BASE/VIAL A074885 002 Dec 19, 1997 Feb DISC
 ACYCLOVIR SODIUM
 >D> AP BEDFORD EQ 500MG BASE/VIAL A074596 002 Apr 22, 1997 Feb DISC
 >A> @ EQ 500MG BASE/VIAL A074596 002 Apr 22, 1997 Feb DISC
 >D> + EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Feb CTEC
 >A> @ EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Feb DISC
 >A> AP + EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Feb CTEC
 >A> AP HIKMA PHARMS LLC EQ 500MG BASE/VIAL A205771 001 Feb 29, 2016 Feb NEWA
 >A> + EQ 1GM BASE/VIAL A205771 002 Feb 29, 2016 Feb CRLD

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

>A> AP EQ 1GM BASE/VIAL A205771 002 Feb 29, 2016 Feb NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

AB UNICHEM LABS LTD 10MG A203192 001 Jan 28, 2016 Jan NEWA

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM

AB SEBELA IRELAND LTD 100MG N016084 001 Jan CAHN

AB + 300MG N016084 002 Jan CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL
ALMOTRIPTAN MALATE

>A> AB AJANTA PHARMA LTD EQ 6.25MG BASE A205523 001 Mar 03, 2016 Feb NEWA

>A> AB EQ 12.5MG BASE A205523 002 Mar 03, 2016 Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL
LOTRONEX

>D> AB PROMETHEUS LABS EQ 0.5MG BASE N021107 002 Dec 23, 2003 Feb CAHN

>D> AB + EQ 1MG BASE N021107 001 Feb 09, 2000 Feb CAHN

>A> AB SEBELA IRELAND LTD EQ 0.5MG BASE N021107 002 Dec 23, 2003 Feb CAHN

>A> AB + EQ 1MG BASE N021107 001 Feb 09, 2000 Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

@ ACTAVIS LABS FL INC 0.5MG A077198 001 May 13, 2010 Jan DISC

@ 1MG A077198 002 May 13, 2010 Jan DISC

@ 2MG A077198 003 May 13, 2010 Jan DISC

@ 3MG A077198 004 May 13, 2010 Jan DISC

@ IMPAX LABS 0.5MG A077968 004 May 24, 2007 Jan DISC

@ 1MG A077968 003 May 24, 2007 Jan DISC

@ 2MG A077968 002 May 24, 2007 Jan DISC

@ 3MG A077968 001 May 24, 2007 Jan DISC

ALPROSTADIL

SUPPOSITORY; URETHRAL
MUSE

+ MEDA PHARMS 0.125MG N020700 001 Nov 19, 1996 Jan CRLD

+ 0.25MG N020700 002 Nov 19, 1996 Jan CRLD

+ 0.5MG N020700 003 Nov 19, 1996 Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB BIONPHARMA INC 100MG A078720 001 May 29, 2008 Jan CAHN

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>D> AB ASCENT PHARMS INC EQ 2.5MG BASE A206367 001 Dec 10, 2015 Feb CAHN

>D> AB EQ 5MG BASE A206367 002 Dec 10, 2015 Feb CAHN

>D> AB EQ 10MG BASE A206367 003 Dec 10, 2015 Feb CAHN

>A> AB INVAGEN PHARMS EQ 2.5MG BASE A206367 001 Dec 10, 2015 Feb CAHN

>A> AB EQ 5MG BASE A206367 002 Dec 10, 2015 Feb CAHN

>A> AB EQ 10MG BASE A206367 003 Dec 10, 2015 Feb CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP MA GENERAL HOSP 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A207025 001 Feb 03, 2016 Jan NEWA

AP MIDWEST MEDCL 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A204457 001 Nov 18, 2015 Jan NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

>D>	AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb	DISC
>A>		@	250MG	A065016	001	Apr 08, 1999	Feb	DISC
>D>	AB		500MG	A065016	002	Apr 08, 1999	Feb	DISC
>A>		@	500MG	A065016	002	Apr 08, 1999	Feb	DISC

TABLET;ORAL

AMOXICILLIN

>D>	AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb	DISC
>A>		@	500MG	A065059	001	Nov 24, 2000	Feb	DISC
>D>	AB		875MG	A065059	002	Nov 24, 2000	Feb	DISC
>A>		@	875MG	A065059	002	Nov 24, 2000	Feb	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

>D>	AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb	DISC
>A>		@	125MG	A065021	001	Dec 23, 1999	Feb	DISC
>D>	AB		250MG	A065021	002	Dec 23, 1999	Feb	DISC
>A>		@	250MG	A065021	002	Dec 23, 1999	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+		VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008	Jan	CAHN
---	--	----------------------	-------	---------	-----	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

>A> FOR SUSPENSION;ORAL

>A> AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR
>D>	AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
>A>		@	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
>A>		@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
>D>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC
>A>		@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC

>D> SUSPENSION;ORAL

>D> AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
>D>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SUN PHARM INDS LTD	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb	DISC
>A>		@	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb	DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb	DISC
>A>		@	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb	DISC
>D>	AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb	DISC
>A>		@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb	DISC

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

		NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan	NEWA
			EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan	NEWA
			EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan	NEWA
			EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan	NEWA
			EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan	NEWA
			EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

>D>		TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb	CTNA
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb	CTNA
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb	CTNA
>D>	AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb	CTNA
>D>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb	CTNA
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb	CTNA

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
>A>	AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
>A>	AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
>A>	AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
>A>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB	AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB	AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB	AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB	AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB	AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB	AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

>D>	AA	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
>A>	AA	+	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@	TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jan CAHN
---	---------------------	--	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@	NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Jan CAHN
---	------------------	-----------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

AB	INGENUS PHARMS NJ	325MG;200MG	A040832	001	Jan 07, 2010	Jan CAHN
----	-------------------	-------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan CAHN
+	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan CRLD
@	MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

>A>	AB	AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Feb NEWA
-----	----	---------------	------------	---------	-----	--------------	----------

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jan CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jan CAHN
AB	TENORMIN	25MG	N018240	004	Apr 09, 1990	Jan CAHN
AB		50MG	N018240	001		Jan CAHN
AB	+	100MG	N018240	002		Jan CAHN

ATENOLOL; CHLORTHALIDONE

	TABLET; ORAL						
	ATENOLOL AND CHLORTHALIDONE						
AB	ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan	CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jan	CAHN
	TENORETIC 100						
AB	+ ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan	CAHN
	TENORETIC 50						
AB	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan	CAHN

AURANOFIN

	CAPSULE; ORAL						
	RIDAURA						
	+ SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan	CAHN

AZATHIOPRINE

	TABLET; ORAL						
	IMURAN						
	@ SEBELA IRELAND LTD	25MG	N016324	002		Jan	CAHN
AB	+	50MG	N016324	001		Jan	CAHN

AZATHIOPRINE SODIUM

	INJECTABLE; INJECTION						
	IMURAN						
	@ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL	N017391	001		Jan	CAHN

AZILSARTAN KAMEDOXOMIL

	TABLET; ORAL						
	EDARBI						
	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jan	CAHN
	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jan	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

	TABLET; ORAL						
	EDARBYCLOL						
	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan	CAHN
	+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan	CAHN

BACLOFEN

	TABLET; ORAL						
	BACLOFEN						
AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan	NEWA

BARIUM SULFATE

	FOR SUSPENSION; ORAL						
	E-Z-HD						
	+ BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan	NEWA
	SUSPENSION; ORAL						
	READI-CAT 2						
	+ BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan	NEWA
	READI-CAT 2 SMOOTHIES						
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan	NEWA

BENAZEPRIL HYDROCHLORIDE

	TABLET; ORAL						
	BENAZEPRIL HYDROCHLORIDE						
	@ ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan	DISC
	@	10MG	A076267	002	Feb 11, 2004	Jan	DISC
	@	20MG	A076267	003	Feb 11, 2004	Jan	DISC
	@	40MG	A076267	004	Feb 11, 2004	Jan	DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET; ORAL						
	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@ ACTAVIS LABS FL INC	5MG;6.25MG	A076342	001	Feb 11, 2004	Jan	DISC
	@	10MG;12.5MG	A076342	002	Feb 11, 2004	Jan	DISC
	@	20MG;12.5MG	A076342	003	Feb 11, 2004	Jan	DISC
	@	20MG;25MG	A076342	004	Feb 11, 2004	Jan	DISC

BENZONATATE

CAPSULE;ORAL
 BENZONATATE
 AA BIONPHARMA INC 100MG A081297 001 Jan 29, 1993 Jan CAHN
 AA 200MG A081297 002 Oct 30, 2007 Jan CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL
 BENZAMYCIN PAK
 >A> + CUTANEA 5%;3% N050769 001 Nov 27, 2000 Feb CAHN
 >D> + VALEANT LUXEMBOURG 5%;3% N050769 001 Nov 27, 2000 Feb CAHN

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL
 SERNIVO
 >A> + PROMIUS PHARMA LLC EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Feb NEWA

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
 BETAXOLOL HYDROCHLORIDE
 AT TELIGENT PHARMA INC EQ 0.5% BASE A075630 001 Apr 12, 2001 Jan CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL
 HELIDAC
 @ SEBELA IRELAND LTD 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N050719 001 Aug 15, 1996 Jan CAHN
 N/A,500MG

BRIVARACETAM

>A> SOLUTION;INTRAVENOUS
 >A> BRIVIACT
 >A> + UBC INC 50MG/5ML (10MG/ML) N205837 001 Feb 18, 2016 Feb NEWA
 >A> SOLUTION;ORAL
 >A> BRIVIACT
 >A> + UCB INC 10MG/ML N205838 001 Feb 18, 2016 Feb NEWA
 >A> TABLET;ORAL
 >A> BRIVIACT
 >A> UCB INC 10MG N205836 001 Feb 18, 2016 Feb NEWA
 >A> 25MG N205836 002 Feb 18, 2016 Feb NEWA
 >A> 50MG N205836 003 Feb 18, 2016 Feb NEWA
 >A> 75MG N205836 004 Feb 18, 2016 Feb NEWA
 >A> + 100MG N205836 005 Feb 18, 2016 Feb NEWA

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL
 BROMOCRIPTINE MESYLATE
 AB + MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005 Jan CRLD
 PARLODEL
 @ US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Jan DISC
 TABLET;ORAL
 BROMOCRIPTINE MESYLATE
 >D> AB LEK PHARMS EQ 2.5MG BASE A074631 001 Jan 13, 1998 Feb CAHN
 AB + PADDOCK LLC EQ 2.5MG BASE A077646 001 Oct 01, 2008 Jan CRLD
 >A> AB SANDOZ INC EQ 2.5MG BASE A074631 001 Jan 13, 1998 Feb CAHN
 PARLODEL
 @ US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Jan DISC

BUDESONIDE

CAPSULE;ORAL
 ENTOCORT EC
 AB + ELAN PHARMA INTL LTD 3MG N021324 001 Oct 02, 2001 Jan CAHN
 SUSPENSION;INHALATION
 BUDESONIDE
 >A> AN TEVA PHARMS USA 1MG/2ML A204548 001 Mar 08, 2016 Feb NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HYDROCHLORIDE

AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan	NEWA	
AB1		150MG	A206674	002	Feb 09, 2016	Jan	NEWA	
AB1		200MG	A206674	003	Feb 09, 2016	Jan	NEWA	
>A>	AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb	NEWA
>A>	AB1		150MG	A205794	002	Mar 01, 2016	Feb	NEWA
>A>	AB1		200MG	A205794	003	Mar 01, 2016	Feb	NEWA

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE
@ CLARIS

		2MG/ML	A075697	001	Oct 23, 2001	Jan	CAHN
--	--	--------	---------	-----	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

+	HORIZON PHARMA	100MG; 2MG	A086557	001	Oct 04, 1983	Jan	CAHN
---	----------------	------------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

AB	BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan	CAHN

INJECTABLE; INJECTION
CALCITRIOL

>D>	AP	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb	CTEC
>A>			0.001MG/ML	A078066	001	Jan 29, 2008	Feb	CTEC
>D>	AP	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb	DISC
>A>		@	0.001MG/ML	A076206	001	Sep 17, 2003	Feb	DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb	DISC
>A>		@	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	002		Feb	DISC

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb	DISC
>A>		@	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	003		Feb	DISC

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb	DISC
>A>		@	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988	Feb	DISC

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb	DISC
>A>		@	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001		Feb	DISC

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	Feb	DISC
>A>		@	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982	Feb	DISC

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982	Feb	DISC
>A>		@	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982	Feb	DISC

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988	Feb	DISC
>A>		@	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988	Feb	DISC

SOLUTION;INTRAPERITONEAL

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
MG/100ML;538MG/100ML;448MG/100ML

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N 018379	006	Jul 07, 1982	Feb DISC	
>A>	@		25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N 018379	006	Jul 07, 1982	Feb DISC	
>D>	AT	DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N 017512	010	Nov 18, 1985	Feb CTEC
>A>				25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N 017512	010	Nov 18, 1985	Feb CTEC
>D>	AT	DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N 017512	011	Nov 18, 1985	Feb CTEC
>A>				25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N 017512	011	Nov 18, 1985	Feb CTEC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ SANDOZ 12.5MG
@ 25MG
@ 50MG
@ 100MG

A 074363 001 Nov 09, 1995 Jan DISC
A 074363 002 Nov 09, 1995 Jan DISC
A 074363 003 Nov 09, 1995 Jan DISC
A 074363 004 Nov 09, 1995 Jan DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB MYLAN IRELAND LTD 100MG
AB 200MG
AB 300MG

A 076697 001 May 20, 2011 Jan CAHN
A 076697 002 May 20, 2011 Jan CAHN
A 076697 003 May 20, 2011 Jan CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

>A> AB EDENBRIDGE PHARMS 25MG

A 205304 001 Feb 17, 2016 Feb NEWA

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

>D> AP EBWE PHARMA 50MG/5ML (10MG/ML)
>D> AP 150MG/15ML (10MG/ML)
>D> AP 450MG/45ML (10MG/ML)
>A> AP SANDOZ INC 50MG/5ML (10MG/ML)
>A> AP 150MG/15ML (10MG/ML)
>A> AP 450MG/45ML (10MG/ML)

A 078280 001 May 08, 2008 Feb CAHN
A 078280 002 May 08, 2008 Feb CAHN
A 078280 003 May 08, 2008 Feb CAHN
A 078280 001 May 08, 2008 Feb CAHN
A 078280 002 May 08, 2008 Feb CAHN
A 078280 003 May 08, 2008 Feb CAHN

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

>D> + ONYX PHARMS 60MG/VIAL
>A> + ONYX THERAP 60MG/VIAL

N 202714 001 Jul 20, 2012 Feb CAHN
N 202714 001 Jul 20, 2012 Feb CAHN

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA INGENUS PHARMS NJ 350MG

A 040823 001 Oct 22, 2008 Jan CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

>D> RANBAXY EQ 125MG BASE/5ML
>A> @ SUN PHARM INDS LTD EQ 125MG BASE/5ML
>D> AB EQ 250MG BASE/5ML
>A> @ EQ 250MG BASE/5ML
>D> AB EQ 500MG BASE/5ML
>A> @ EQ 500MG BASE/5ML

A 065115 001 Mar 26, 2003 Feb DISC
A 065115 001 Mar 26, 2003 Feb DISC
A 065115 002 Mar 26, 2003 Feb DISC
A 065115 002 Mar 26, 2003 Feb DISC
A 065115 003 Mar 26, 2003 Feb DISC
A 065115 003 Mar 26, 2003 Feb DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP HOSPIRA INC EQ 1GM BASE/VIAL A201654 001 Feb 03, 2016 Jan NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP QILU PHARM CO LTD EQ 500MG BASE/VIAL A203704 001 Feb 01, 2016 Jan NEWA
AP EQ 1GM BASE/VIAL A203704 002 Feb 01, 2016 Jan NEWA
AP EQ 2GM BASE/VIAL A203704 003 Feb 01, 2016 Jan NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

>A> AP HOSPIRA INC EQ 1GM BASE/VIAL A203132 001 Feb 19, 2016 Feb NEWA
>A> AP EQ 2GM BASE/VIAL A203132 002 Feb 19, 2016 Feb NEWA

CLAFORAN

AP + US PHARM HOLDINGS EQ 500MG BASE/VIAL N050547 001 Jan CAHN
AP + EQ 1GM BASE/VIAL N050547 002 Jan CAHN
AP + EQ 2GM BASE/VIAL N050547 003 Jan CAHN
AP + EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Jan CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ US PHARM HOLDINGS EQ 20MG BASE/ML N050596 002 May 20, 1985 Jan CAHN
+ EQ 40MG BASE/ML N050596 004 May 20, 1985 Jan CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
@ US PHARM HOLDINGS EQ 20MG BASE/ML N050596 001 May 20, 1985 Jan CAHN
@ EQ 40MG BASE/ML N050596 003 May 20, 1985 Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

@ TELIGENT PHARMA INC EQ 1GM BASE/VIAL A063293 001 Apr 29, 1993 Jan CAHN
>D> @ EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Feb CMFD
>A> AP EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Feb CMFD
@ EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Jan CAHN
@ EQ 2GM BASE/VIAL A063293 002 Apr 29, 1993 Jan CAHN
>D> @ EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Feb CMFD
>A> AP EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Feb CMFD
@ EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Jan CAHN
@ EQ 10GM BASE/VIAL N050588 003 Apr 25, 1988 Jan CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

>D> AB SUN PHARM INDS LTD EQ 50MG BASE/5ML A065082 001 May 31, 2002 Feb DISC
>A> @ EQ 50MG BASE/5ML A065082 001 May 31, 2002 Feb DISC
>D> AB EQ 100MG BASE/5ML A065082 002 May 31, 2002 Feb DISC
>A> @ EQ 100MG BASE/5ML A065082 002 May 31, 2002 Feb DISC

TABLET; ORAL

CEFPODOXIME PROXETIL

>D> AB SUN PHARM INDS LTD EQ 100MG BASE A065083 001 Aug 20, 2003 Feb DISC
>A> @ EQ 100MG BASE A065083 001 Aug 20, 2003 Feb DISC
>D> AB EQ 200MG BASE A065083 002 Aug 20, 2003 Feb DISC
>A> @ EQ 200MG BASE A065083 002 Aug 20, 2003 Feb DISC

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL
CEFTIN

>D> AB GLAXOSMITHKLINE EQ 125MG BASE/5ML N050672 001 Jun 30, 1994 Feb CTEC
>A> EQ 125MG BASE/5ML N050672 001 Jun 30, 1994 Feb CTEC
>D> AB + EQ 250MG BASE/5ML N050672 002 Apr 29, 1997 Feb CTEC
>A> + EQ 250MG BASE/5ML N050672 002 Apr 29, 1997 Feb CTEC

CEFUROXIME AXETIL

>D> AB SUN PHARM INDS LTD EQ 125MG BASE/5ML A065323 001 Feb 05, 2008 Feb DISC
>A> @ EQ 125MG BASE/5ML A065323 001 Feb 05, 2008 Feb DISC
>D> AB EQ 250MG BASE/5ML A065323 002 Feb 05, 2008 Feb DISC
>A> @ EQ 250MG BASE/5ML A065323 002 Feb 05, 2008 Feb DISC

TABLET; ORAL

CEFUROXIME AXETIL

>D> AB SUN PHARM INDS LTD EQ 125MG BASE A065118 001 Apr 25, 2003 Feb DISC

TABLET;ORAL

CEFUROXIME AXETIL

>A>	@	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb	DISC
>D>	AB	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC
>A>	@	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC
>D>	AB	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC
>A>	@	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan	CAHN
		ZINACEF IN PLASTIC CONTAINER						
		@ IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan	CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan	CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS						
		ZINACEF						
AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan	CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB		AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan	NEWA
AB			100MG	A206827	002	Feb 01, 2016	Jan	NEWA
AB			200MG	A206827	003	Feb 01, 2016	Jan	NEWA
AB			400MG	A206827	004	Feb 01, 2016	Jan	NEWA
>A>	AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb	NEWA
>A>	AB		100MG	A204590	002	Mar 16, 2016	Feb	NEWA
>A>	AB		200MG	A204590	003	Mar 16, 2016	Feb	NEWA
>A>	AB		400MG	A204590	004	Mar 16, 2016	Feb	NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

>D>	AB	RANBAXY	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb	DISC
>A>	@	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb	DISC
>D>	AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb	DISC
>A>	@		EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

AT		COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan	NEWA
----	--	----------------------	-------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	AA	COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb	CAHN
>A>	AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb	CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		MYLAN	25MG	A086831	002		Jan	CTEC
AB		SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan	NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>A>	@	AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988	Feb	CAHN
>A>	@		500MG	A089853	001	May 04, 1988	Feb	CAHN
>D>	@	SANDOZ	250MG	A089852	001	May 04, 1988	Feb	CAHN
>D>	@		500MG	A089853	001	May 04, 1988	Feb	CAHN

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

+		TAKEDA GMBH	0.08MG/INH	N021658	002	Jan 10, 2008	Jan	CRLD
---	--	-------------	------------	---------	-----	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC 212.6MG;EQ 287.5MG BASE A077417 001 Nov 30, 2010 Jan DISC
@ 425.2MG;EQ 574.9MG BASE A077809 001 Nov 30, 2010 Jan DISC

CLARITHROMYCIN

TABLET, EXTENDED RELEASE;ORAL
CLARITHROMYCIN

>A> AB ALLIED PHARMA INC 500MG A203243 001 Feb 29, 2016 Feb NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL
VELTIN

BX + AQUA PHARMS LLC 1.2%;0.025% N050803 001 Jul 16, 2010 Jan CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL
ANAFRANIL

AB + MALLINCKRODT LLC 25MG N019906 001 Dec 29, 1989 Jan CRLD
AB 50MG N019906 002 Dec 29, 1989 Jan CRLD

CLONIDINE HYDROCHLORIDE

TABLET;ORAL
CLONIDINE HYDROCHLORIDE

>A> @ AUROLIFE PHARMA LLC 0.1MG A070887 001 Aug 31, 1988 Feb CAHN
>A> @ 0.2MG A070886 001 Aug 31, 1988 Feb CAHN
>A> @ 0.3MG A071294 001 Aug 31, 1988 Feb CAHN
>D> @ SANDOZ 0.1MG A070887 001 Aug 31, 1988 Feb CAHN
>D> @ 0.2MG A070886 001 Aug 31, 1988 Feb CAHN
>D> @ 0.3MG A071294 001 Aug 31, 1988 Feb CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL
CLORAZEPATE DIPOTASSIUM

>A> @ AUROLIFE PHARMA LLC 7.5MG A072220 001 Aug 26, 1988 Feb CAHN
>A> @ 15MG A072112 001 Aug 26, 1988 Feb CAHN
>D> @ SANDOZ 7.5MG A072220 001 Aug 26, 1988 Feb CAHN
>D> @ 15MG A072112 001 Aug 26, 1988 Feb CAHN

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

>A> @ AUROLIFE PHARMA LLC 15MG A072514 001 May 11, 1990 Feb CAHN
>D> @ SANDOZ 15MG A072514 001 May 11, 1990 Feb CAHN

COLCHICINE; PROBENECID

TABLET;ORAL
PROBENECID AND COLCHICINE

AB INGENUS PHARMS NJ 0.5MG;500MG A040618 001 May 13, 2008 Jan CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC
COLY-MYCIN S

>A> + ENDO PHARMS INC EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG N050356 001 Feb CAHN
>D> + PAR STERILE PRODUCTS EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG N050356 001 Feb CAHN
BASE/ML;0.5MG/ML
BASE/ML;0.5MG/ML

CORTICOTROPIN

INJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL

>A> @ ANI PHARMS 40 UNITS/ML N008975 001 Feb CAHN
>A> @ 80 UNITS/ML N008975 002 Feb CAHN
>D> @ ORGANON USA INC 40 UNITS/ML N008975 001 Feb CAHN
>D> @ 80 UNITS/ML N008975 002 Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION
CORTROPHIN-ZINC

>A> @ ANI PHARMS 40 UNITS/ML N009854 001 Feb CAHN
>D> @ ORGANON USA INC 40 UNITS/ML N009854 001 Feb CAHN

CYANOCOBALAMIN

SPRAY, METERED;NASAL
NASCOBAL

>A>	+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb CAHN
>D>	+	PAR PHARM	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA		INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan CAHN
----	--	-------------------	-----	---------	-----	--------------	----------

DACTINOMYCIN

INJECTABLE;INJECTION
DACTINOMYCIN

>D>	AP		EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb DISC
>A>		@		0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb DISC

DALBAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)
DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jan CDFR
---	---------------------	--------------------	---------	-----	--------------	----------

DANTROLENE SODIUM

INJECTABLE;INJECTION
DANTROLENE SODIUM

>A>	AP		MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Feb NEWA
-----	----	--	---------------------	-----------	---------	-----	--------------	----------

DAPSONE

GEL;TOPICAL
ACZONE

>A>	+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Feb NEWA
-----	---	--------------	------	---------	-----	--------------	----------

DAPTOMYCIN

POWDER;INTRAVENOUS
CUBICIN

AP	+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR
----	---	--------	------------	---------	-----	--------------	----------

AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
----	--	-------------	------------	---------	-----	--------------	----------

POWDER;IV (INFUSION)
CUBICIN

@	CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR
---	--------	------------	---------	-----	--------------	----------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
ENABLEX

AB		ALLERGAN PHARMS INTL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
----	--	----------------------	---------------	---------	-----	--------------	----------

AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN
----	---	--	--------------	---------	-----	--------------	----------

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

AB			250MG	A203560	002	Jan 26, 2016	Jan NEWA
----	--	--	-------	---------	-----	--------------	----------

AB			500MG	A203560	003	Jan 26, 2016	Jan NEWA
----	--	--	-------	---------	-----	--------------	----------

EXJADE

AB		NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
----	--	----------	-------	---------	-----	--------------	----------

AB			250MG	N021882	002	Nov 02, 2005	Jan CFTG
----	--	--	-------	---------	-----	--------------	----------

AB	+		500MG	N021882	003	Nov 02, 2005	Jan CFTG
----	---	--	-------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
NORPRAMIN

AB		US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
----	--	-------------------	------	---------	-----	--------------	----------

AB			25MG	N014399	001		Jan CAHN
----	--	--	------	---------	-----	--	----------

AB			50MG	N014399	003		Jan CAHN
----	--	--	------	---------	-----	--	----------

AB			75MG	N014399	004		Jan CAHN
----	--	--	------	---------	-----	--	----------

AB	+		100MG	N014399	005		Jan CAHN
----	---	--	-------	---------	-----	--	----------

AB			150MG	N014399	006		Jan CAHN
----	--	--	-------	---------	-----	--	----------

DESONIDE

CREAM;TOPICAL
DESONIDE

AB G AND W LABS INC 0.05% A074027 001 Sep 28, 1992 Jan CAHN

DESOXIMETASONE

OINTMENT;TOPICAL
DESOXIMETASONE

>A> AB TELIGENT PHARMA INC 0.25% A208101 001 Feb 25, 2016 Feb NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

>A> AB ROXANE EQ 50MG BASE A204082 001 Feb 16, 2016 Feb NEWA
>A> AB EQ 100MG BASE A204083 001 Feb 16, 2016 Feb NEWA

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB

+ TAKEDA PHARMS USA 30MG N208056 001 Jan 26, 2016 Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP ACCORD HLTHCARE INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204023 001 Feb 09, 2016 Jan NEWA

PRECEDEX

>D> HOSPIRA EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) N021038 004 Nov 14, 2014 Feb CRLD
>A> + EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) N021038 004 Nov 14, 2014 Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A> AB SUN PHARM INDS 2.5MG A201231 001 Sep 24, 2015 Feb CAHN
>A> AB 5MG A201231 002 Sep 24, 2015 Feb CAHN
>A> AB 10MG A201231 003 Sep 24, 2015 Feb CAHN
>D> AB SUN PHARM INDS LTD 2.5MG A201231 001 Sep 24, 2015 Feb CAHN
>D> AB 5MG A201231 002 Sep 24, 2015 Feb CAHN
>D> AB 10MG A201231 003 Sep 24, 2015 Feb CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

AB MYLAN PHARMS INC 5MG A206735 001 Jan 27, 2016 Jan NEWA
AB 10MG A206735 002 Jan 27, 2016 Jan NEWA
AB 15MG A206735 003 Jan 27, 2016 Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>A> AA NOVEL LABS INC 5MG A204330 001 Mar 16, 2016 Feb NEWA
>A> AA 10MG A204330 002 Mar 16, 2016 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DESTROMETHORPHAN HYDROBROMIDE

>D> @ ANI PHARMS 15MG/5ML;6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1
>A> @ ANI PHARMS 15MG/5ML;6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

>A> BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML N017484 001 Feb CMS1
>D> BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML N017484 001 Feb CMS1

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

	INJECTABLE; INJECTION							
	DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER							
>D>	@ BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840	001	Jun 29, 1983	Feb	CMS1	
	DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER							
>A>	@ BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840	001	Jun 29, 1983	Feb	CMS1	

DIAZEPAM

	INJECTABLE; INJECTION							
	DIAZEPAM							
	@ EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan	CAHN	
	TABLET; ORAL							
	DIAZEPAM							
	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan	NEWA	
		5MG	A070228	003	Sep 26, 1985	Jan	NEWA	

DICLOFENAC POTASSIUM

	CAPSULE; ORAL							
	DICLOFENAC POTASSIUM							
>A> AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb	NEWA	
	ZIPSOR							
>D>	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb	CFTG	
>A> AB	+	25MG	N022202	001	Jun 16, 2009	Feb	CFTG	

DICLOFENAC SODIUM

	SOLUTION/DROPS; OPHTHALMIC							
	DICLOFENAC SODIUM							
AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan	CAHN	
	TABLET, EXTENDED RELEASE; ORAL							
	DICLOFENAC SODIUM							
>D> AB	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb	CRLD	
>A> AB	+	100MG	A075910	001	Jan 07, 2002	Feb	CRLD	
>D>	VOLTAREN-XR							
>D> AB	+ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb	DISC	
>A>	@	100MG	N020254	001	Mar 08, 1996	Feb	DISC	

DICYCLOMINE HYDROCHLORIDE

	SYRUP; ORAL							
	BENTYL							
	@ APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Jan	DISC	
	DICYCLOMINE HYDROCHLORIDE							
	+ MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan	CRLD	

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL							
	DILTIAZEM HYDROCHLORIDE							
	@ ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan	DISC	
	@	180MG	A074852	002	Oct 10, 1997	Jan	DISC	
	@	240MG	A074852	003	Oct 10, 1997	Jan	DISC	
AB3	VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan	CAHN	
AB3		180MG	A075116	002	Dec 23, 1999	Jan	CAHN	
AB3		240MG	A075116	003	Dec 23, 1999	Jan	CAHN	
AB3		300MG	A075116	004	Dec 23, 1999	Jan	CAHN	

DINOPROSTONE

	INSERT, EXTENDED RELEASE; VAGINAL							
	CERVIDIL							
	+ FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan	CAHN	

DIPHENHYDRAMINE HYDROCHLORIDE

	CAPSULE; ORAL							
	DIPHENHYDRAMINE HYDROCHLORIDE							
>A>	@ HIKMA PHARMS	50MG	A083567	001		Feb	CAHN	
>D>	@ HIKMA PHARMS LLC	50MG	A083567	001		Feb	CAHN	

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

>A>	@ AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
>A>	@	EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN
>D>	@ SANDOZ	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
>D>	@	EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB	ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

>D>	AB	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb	DISC
>A>		@	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb	DISC
>D>	AB		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb	DISC
>A>		@	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb	DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

@ TELIGENT PHARMA INC EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995 Jan CAHN

DOCETAXEL

SOLUTION;IV (INFUSION)

DOCETAXEL

EAGLE PHARMS

20MG/ML (20MG/ML)

N205934 001 Dec 22, 2015 Jan CAHN

80MG/4ML (20MG/ML)

N205934 002 Dec 22, 2015 Jan CAHN

160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015 Jan CAHN

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

+ US PHARM HOLDINGS

12.5MG/0.625ML (20MG/ML)

N020624 002 Sep 11, 1997 Jan CAHN

+

100MG/5ML (20MG/ML)

N020624 001 Sep 11, 1997 Jan CAHN

+

500MG/25ML (20MG/ML)

N020624 003 Dec 11, 2001 Jan CAHN

TABLET;ORAL

ANZEMET

US PHARM HOLDINGS

50MG

N020623 001 Sep 11, 1997 Jan CAHN

+

100MG

N020623 002 Sep 11, 1997 Jan CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb	NEWA
-----	----	---------------	------	---------	-----	--------------	-----	------

	AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan	NEWA
--	----	---------------------	------	---------	-----	--------------	-----	------

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	NEWA
----	------------------	-------------	---------	-----	--------------	-----	------

AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	NEWA
----	--	-------------	---------	-----	--------------	-----	------

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

>A>	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb	NEWA
-----	----	----------------------	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb	NEWA
-----	----	--	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb	NEWA
-----	----	--	---------------	---------	-----	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan	CAHN	
>A>	AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb	NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION
TENSILON

@	TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan	CAHN
	TENSILON PRESERVATIVE FREE						
@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan	CAHN

EFAVIRENZ

TABLET;ORAL

>A>	AB	MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb	NEWA
		SUSTIVA						
>D>	+	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb	CFTG
>A>	AB	+	600MG	N021360	002	Feb 01, 2002	Feb	CFTG

ELBASVIR; GRAZOPREVIR

TABLET;ORAL
ZEPATIER

+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan	NEWA
---	-------------------	------------	---------	-----	--------------	-----	------

EPINEPHRINE HYDROCHLORIDE

>D>		SOLUTION;IV (INFUSION), INTRAOCULAR						
>D>		EPINEPHRINE						
>D>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb	CDFR
>A>		SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS						
>A>		EPINEPHRINE						
>A>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb	CDFR

ERGOCALCIFEROL

CAPSULE;ORAL
DRISDOL

AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan	CAHN
		VITAMIN D						
AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan	CAHN

ERYTHROMYCIN

SOLUTION;TOPICAL

>D>		C-SOLVE-2						
>D>	AT	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb	DISC
>A>		@	2%	A062468	001	Jul 03, 1985	Feb	DISC
>D>		ERYTHRO-STATIN						
>D>	AT	HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb	DISC
>A>		@	2%	A064101	001	Oct 22, 1996	Feb	DISC
		ERYTHROMYCIN						
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan	CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan	CRLD

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL
FEMRING

		ALLERGAN PHARMS INTL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN
+			EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN

TABLET;ORAL
FEMTRACE

		ALLERGAN PHARMS INTL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN
			0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN
+			1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan	NEWA
		ZOVIA 1/50E-28						
AB	+	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan	CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET, CHEWABLE;ORAL							
	FEMCON FE							
AB	+	ALLERGAN PHARMS INTL 0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan	CAHN	
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	+	ALLERGAN PHARMS INTL 0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL							
	FEMHRT							
AB		ALLERGAN PHARMS INTL 0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan	CAHN	
	@	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan	CAHN	
	LO LOESTRIN FE							
	+	ALLERGAN PHARMS INTL 0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan	CAHN	
	TABLET;ORAL-21							
	ESTROSTEP 21							
	@	ALLERGAN PHARMS INTL 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan	CAHN	
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		GLENMARK PHARMS LTD 0.02MG;1MG	A206969	001	Jan 20, 2016	Jan	NEWA	
	TABLET;ORAL-28							
	ESTROSTEP FE							
AB	+	ALLERGAN PHARMS INTL 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan	CAHN	
	TABLET, CHEWABLE;ORAL							
	MINASTRIN 24 FE							
	+	ALLERGAN PHARMS INTL 0.02MG;1MG	N203667	001	May 08, 2013	Jan	CAHN	
	TABLET, CHEWABLE, TABLET;ORAL							
	LO MINASTRIN FE							
	+	ALLERGAN PHARMS INTL 0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	CAHN	

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET;ORAL-28							
	NORGESTIMATE AND ETHINYL ESTRADIOL							
>A>	AB	GLENMARK PHARMS LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Feb	NEWA	
		15MG,0.25MG						
	AB	JAI PHARMA LTD 0.035MG, 0.035MG, 0.035MG;0.18MG,	A201897	001	Jan 27, 2016	Jan	NEWA	
		0.215MG, 0.25MG						
	AB	0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA	

ETHOSUXIMIDE

	CAPSULE;ORAL							
	ETHOSUXIMIDE							
AB		BIONPHARMA INC 250MG	A040430	001	Oct 28, 2002	Jan	CAHN	

ETODOLAC

	CAPSULE;ORAL							
	ETODOLAC							
>D>	@	AAIPHARMA LLC 300MG	A074929	001	Jan 30, 1998	Feb	CAHN	
>A>	@	LEHIGH VALLEY 300MG	A074929	001	Jan 30, 1998	Feb	CAHN	

ETOMIDATE

	INJECTABLE;INJECTION							
	ETOMIDATE							
>A>	AP	HIKMA FARMACEUTICA 2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA	

EXEMESTANE

	TABLET;ORAL							
	EXEMESTANE							
AB		ALVOGEN MALTA 25MG	A200898	001	Jul 28, 2014	Jan	CAHN	

EXENATIDE SYNTHETIC

	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
	BYDUREON PEN							
>A>	+	ASTRAZENECA AB 2MG	N022200	002	Feb 28, 2014	Feb	NEWA	

FENOPROFEN CALCIUM

	CAPSULE;ORAL							
	FENOPROFEN CALCIUM							
>A>	@	AUROLIFE PHARMA LLC EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb	CAHN	
>D>	@	SANDOZ EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb	CAHN	

TABLET;ORAL

FENOPROFEN CALCIUM

>A>	@ AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
>D>	@ SANDOZ	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA
----	-------	------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

	@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
	@	8MG	A204827	002	Dec 10, 2015	Jan DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

>D>	AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
>A>		@	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
>D>	AB		200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC
>A>		@	200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan DISC
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>D>	AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN
>A>	AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUOROURACIL

INJECTABLE;INJECTION
FLUOROURACIL

>A>	AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
>A>	AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
		@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDE

TABLET;ORAL

SARAFEM

AB1		ALLERGAN PHARMS INTL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1			EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1	+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

>A>		@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb CAHN
>A>		@	30MG	A071717	001	Jul 31, 1991	Feb CAHN
>D>		@ SANDOZ	15MG	A071716	001	Jul 31, 1991	Feb CAHN
>D>		@	30MG	A071717	001	Jul 31, 1991	Feb CAHN

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

>A>		@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb CAHN
>A>		@	100MG	A074448	002	Jul 28, 1995	Feb CAHN
>D>		@ SANDOZ	50MG	A074448	001	Jul 28, 1995	Feb CAHN
>D>		@	100MG	A074448	002	Jul 28, 1995	Feb CAHN

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL
FLUVASTATIN SODIUM

AB		TEVA PHARMS USA	80MG	A079011	001	Jan 27, 2016	Jan NEWA
----	--	-----------------	------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

>A>	@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb CAHN
>A>	@		50MG	A075900	002	Feb 23, 2006	Feb CAHN
>A>	@		100MG	A075900	003	Feb 23, 2006	Feb CAHN
>D>	@	SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006	Feb CAHN
>D>	@		50MG	A075900	002	Feb 23, 2006	Feb CAHN
>D>	@		100MG	A075900	003	Feb 23, 2006	Feb CAHN

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

	@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
	@		20MG	A076620	002	Oct 15, 2004	Jan DISC
	@		40MG	A076620	003	Oct 15, 2004	Jan DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan DISC
	@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan DISC
>D> AB		SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
>A>	@		10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
>D> AB			20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC
>A>	@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

>A> AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
--------	--	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

>D> AP	+	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
		LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb DISC
>A>	@		10MG/ML	N018579	001	Nov 30, 1983	Feb DISC

TABLET;ORAL

LASIX

AB		US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
AB			40MG	N016273	001		Jan CAHN
AB	+		80MG	N016273	003		Jan CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>A> AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
>A> AB			300MG	A204989	002	Feb 18, 2016	Feb NEWA
>A> AB			400MG	A204989	003	Feb 18, 2016	Feb NEWA

SOLUTION;ORAL

GABAPENTIN

>A> AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
--------	--	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

GABAPENTIN

AB		SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB			800MG	A205101	002	Feb 04, 2016	Jan NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

>D> AB		IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb DISC
>A>	@		EQ 8MG BASE	A078484	001	May 27, 2009	Feb DISC
>D> AB			EQ 16MG BASE	A078484	002	May 27, 2009	Feb DISC
>A>	@		EQ 16MG BASE	A078484	002	May 27, 2009	Feb DISC
>D> AB			EQ 24MG BASE	A078484	003	May 27, 2009	Feb DISC
>A>	@		EQ 24MG BASE	A078484	003	May 27, 2009	Feb DISC

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A 076995	001	Apr 27, 2010	Jan	DISC
@		2MG	A 076995	002	Apr 27, 2010	Jan	DISC
@		4MG	A 076995	003	Apr 27, 2010	Jan	DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG;250MG	A 076731	001	Nov 19, 2004	Jan	DISC
@		2.5MG;500MG	A 076731	002	Nov 19, 2004	Jan	DISC
@		5MG;500MG	A 076731	003	Nov 19, 2004	Jan	DISC
>A>	AB	ZYDUS PHARMS USA INC	A 206748	001	Feb 29, 2016	Feb	NEWA
>A>	AB		A 206748	002	Feb 29, 2016	Feb	NEWA
>A>	AB		A 206748	003	Feb 29, 2016	Feb	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>D>	AP	HIKMA FARMACEUTICA	0.2MG/ML	A 090963	001	Sep 21, 2011	Feb	CRLD
>A>	AP	+	0.2MG/ML	A 090963	001	Sep 21, 2011	Feb	CRLD
>D>		ROBINUL						
>D>	AP	+	EUROHLTH INTL SARL	0.2MG/ML	N 017558	001	Feb	DISC
>A>		@	0.2MG/ML	N 017558	001		Feb	DISC

TABLET; ORAL

GLYCOPYRROLATE

AA		RISING PHARMS INC	1MG	A 040821	001	Dec 29, 2008	Jan	CAHN
AA			2MG	A 040821	002	Dec 29, 2008	Jan	CAHN
AA	+	CASPER PHARMA LLC	1MG	N 012827	001		Jan	CAHN
AA	+	CASPER PHARMA LLC	2MG	N 012827	002		Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 078863	001	Jun 30, 2008	Jan	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078880	001	Jun 30, 2008	Jan	CAHN
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078629	001	Dec 23, 2009	Jan	CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078629	002	Dec 23, 2009	Jan	CMS1
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078863	002	Jun 30, 2008	Jan	CAHN

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	ROXANE	2MG	A 071130	001	Feb 17, 1987	Jan	CAHN
@	VINTAGE	0.5MG	A 071235	002	Nov 03, 1986	Jan	CMS1
@		1MG	A 071235	003	Nov 03, 1986	Jan	CMS1
@		5MG	A 071235	004	Nov 03, 1986	Jan	CMS1
@		10MG	A 071235	005	Jul 20, 1987	Jan	CMS1

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@	ACTAVIS ELIZABETH	1.5MG;5MG	A 040295	001	Dec 01, 2000	Jan	CMS1
---	-------------------	-----------	----------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

>A>		@	WATSON LABS	25MG;15MG	A 085827	001	Feb	CMS1
>D>		@	WATSON LABS	25MG;15MG	A 085827	001	Feb	CMS1

HYDROCHLOROTHIAZIDE

	TABLET; ORAL					
	HYDROCHLOROTHIAZIDE					
>A>	@ AUROLIFE PHARMA LLC	25MG	A 083899	001		Feb CAHN
>A>	@	50MG	A 085219	001		Feb CAHN
>D>	@ SANDOZ	25MG	A 083899	001		Feb CAHN
>D>	@	50MG	A 085219	001		Feb CAHN
	ORETIC					
	@ ABBVIE	50MG	N 011971	002		Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

	TABLET; ORAL					
	IRBESARTAN AND HYDROCHLOROTHIAZIDE					
AB	INTL SPECLT CHEMS	12.5MG;150MG	A 203036	001	Jan 15, 2016	Jan NEWA
AB		12.5MG;300MG	A 203036	002	Jan 15, 2016	Jan NEWA
		25MG;300MG	A 203036	003	Jan 15, 2016	Jan NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

	TABLET; ORAL					
	ZESTORETIC					
AB	ALVOGEN MALTA	12.5MG;10MG	N 019888	003	Nov 18, 1993	Jan CAHN
AB	+	12.5MG;20MG	N 019888	001	Sep 20, 1990	Jan CAHN
AB	+	25MG;20MG	N 019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

	TABLET; ORAL					
	VALSARTAN AND HYDROCHLOROTHIAZIDE					
AB	PRINSTON INC	12.5MG;80MG	A 206083	001	Feb 08, 2016	Jan NEWA
AB		12.5MG;160MG	A 206083	002	Feb 08, 2016	Jan NEWA
AB		12.5MG;320MG	A 206083	003	Feb 08, 2016	Jan NEWA
AB		25MG;160MG	A 206083	004	Feb 08, 2016	Jan NEWA
AB		25MG;320MG	A 206083	005	Feb 08, 2016	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

	TABLET; ORAL					
	HYDROCODONE BITARTRATE AND IBUPROFEN					
	@ ACTAVIS LABS FL INC	5MG;200MG	A 077454	001	Jun 23, 2010	Jan DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

	SUSPENSION/DROPS; OTIC					
	PEDIOTIC					
	@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 062822	001	Sep 29, 1987	Jan DISC

HYDROXOCOBALAMIN

	INJECTABLE; INJECTION					
	CYANOKIT					
	@ SERB SA	2.5GM/VIAL (5GM/KIT)	N 022041	002	Dec 15, 2006	Jan CAHN
	+	5GM/VIAL (5GM/KIT)	N 022041	001	Apr 08, 2011	Jan CAHN

HYDROXYCHLOROQUINE SULFATE

	TABLET; ORAL					
	HYDROXYCHLOROQUINE SULFATE					
>D>	@ WATSON LABS	200MG	A 040133	001	Nov 30, 1995	Feb CMFD
>A>	AB	200MG	A 040133	001	Nov 30, 1995	Feb CMFD

HYDROXYPROGESTERONE CAPROATE

	INJECTABLE; INJECTION					
	HYDROXYPROGESTERONE CAPROATE					
	+ ASPEN GLOBAL INC	250MG/ML	A 200271	001	Aug 24, 2015	Jan CAHN
	SOLUTION; INTRAMUSCULAR					
	MAKENA					
>A>	+ LUMARA HEALTH INC	250MG/ML (250MG/ML)	N 021945	002	Feb 19, 2016	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

	TABLET; ORAL					
	HYDROXYZINE HYDROCHLORIDE					
>A>	@ AUROLIFE PHARMA LLC	10MG	A 087869	001	Dec 20, 1982	Feb CAHN
>A>	@	25MG	A 087870	001	Dec 20, 1982	Feb CAHN
>A>	@	50MG	A 087871	001	Dec 20, 1982	Feb CAHN
>D>	@ SANDOZ	10MG	A 087869	001	Dec 20, 1982	Feb CAHN

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

>D> @ 25MG A087870 001 Dec 20, 1982 Feb CAHN
 >D> @ 50MG A087871 001 Dec 20, 1982 Feb CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP ACCORD HLTHCARE EQ 3MG BASE/3ML A206058 001 Feb 05, 2016 Jan NEWA

TABLET;ORAL

IBANDRONATE SODIUM

>A> AB AUROBINDO PHARMA LTD EQ 150MG BASE A204502 001 Mar 11, 2016 Feb NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

>A> @ AUROLIFE PHARMA LLC 300MG A070734 001 Jun 12, 1986 Feb CAHN
 >A> @ 400MG A070735 001 Jun 12, 1986 Feb CAHN
 >A> @ 600MG A070736 001 Jun 12, 1986 Feb CAHN
 >D> @ SANDOZ 300MG A070734 001 Jun 12, 1986 Feb CAHN
 >D> @ 400MG A070735 001 Jun 12, 1986 Feb CAHN
 >D> @ 600MG A070736 001 Jun 12, 1986 Feb CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

>D> AB ROXANE EQ 75MG HCL A091099 001 Apr 16, 2010 Feb CRLD
 >A> AB + EQ 75MG HCL A091099 001 Apr 16, 2010 Feb CRLD
 >D> TOFRANIL-PM
 >D> AB + MALLINCKRODT INC EQ 75MG HCL N017090 001 Feb DISC
 >A> @ EQ 75MG HCL N017090 001 Feb DISC
 >D> AB EQ 100MG HCL N017090 004 Feb DISC
 >A> @ EQ 100MG HCL N017090 004 Feb DISC
 >D> AB EQ 125MG HCL N017090 003 Feb DISC
 >A> @ EQ 125MG HCL N017090 003 Feb DISC
 >D> AB EQ 150MG HCL N017090 002 Feb DISC
 >A> @ EQ 150MG HCL N017090 002 Feb DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

+ MALLINKRODT NUCLEAR 5mCi/0.5ML N019841 001 Sep 27, 1994 Jan CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+ MALLINKRODT NUCLEAR 3mCi/ML N020314 001 Jun 02, 1994 Jan CAHN

INDOCYANINE GREEN

INJECTABLE;INJECTION

INDOCYANINE GREEN

AP DIAGNOSTIC GREEN 25MG/VIAL A040811 001 Nov 21, 2007 Jan CAHN

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXPEN

>D> + NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 002 Jun 16, 2005 Feb DISC
 >A> @ 300 UNITS/3ML (100 UNITS/ML) N021536 002 Jun 16, 2005 Feb DISC

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS

HUMULIN R

+ LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994 Jan CAIN

HUMULIN R KWIKPEN

+ LILLY 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015 Jan NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
 IRINOTECAN HYDROCHLORIDE
 AP SANDOZ INC 40MG/2ML (20MG/ML) A 090137 001 Nov 12, 2009 Jan CAHN
 AP 100MG/5ML (20MG/ML) A 090137 002 Nov 12, 2009 Jan CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION
 ISOSULFAN BLUE
 AP AUROBINDO PHARMA LTD 1% A 206831 001 Feb 02, 2016 Jan NEWA
 AP + MYLAN INSTITUTIONAL 1% A 090874 001 Jul 20, 2010 Jan CTEC

KETOCONAZOLE

TABLET; ORAL
 KETOCONAZOLE
 @ SUN PHARM INDS 200MG A 075314 001 Jun 15, 1999 Jan CAHN

KETOPROFEN

CAPSULE; ORAL
 KETOPROFEN
 >A> @ AUROLIFE PHARMA LLC 50MG A 074024 001 Dec 29, 1995 Feb CAHN
 >A> @ 75MG A 074024 002 Dec 29, 1995 Feb CAHN
 >D> @ SANDOZ 50MG A 074024 001 Dec 29, 1995 Feb CAHN
 >D> @ 75MG A 074024 002 Dec 29, 1995 Feb CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
 LABETALOL HYDROCHLORIDE
 AP SAGENT STRIDES 5MG/ML A 079134 001 Feb 03, 2010 Jan CTNA
 TRANDATE
 @ SEBELA IRELAND LTD 5MG/ML N 019425 001 Dec 31, 1985 Jan CAHN
 TABLET; ORAL
 LABETALOL HYDROCHLORIDE
 AB NOSTRUM LABS INC 100MG A 075215 001 Jul 29, 1999 Jan CAHN
 AB 200MG A 075215 002 Jul 29, 1999 Jan CAHN
 AB 300MG A 075215 003 Jul 29, 1999 Jan CAHN

LAMIVUDINE

TABLET; ORAL
 LAMIVUDINE
 >A> AB MYLAN PHARMS INC 150MG A 204528 001 Mar 04, 2016 Feb NEWA
 >A> AB 300MG A 204528 002 Mar 04, 2016 Feb NEWA

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL
 LAMICTAL XR
 AB + GLAXOSMITHKLINE LLC 200MG N 022115 004 May 29, 2009 Jan CRLD

LETROZOLE

TABLET; ORAL
 LETROZOLE
 AB KREMERS URBAN PHARMS 2.5MG A 091098 001 Jun 03, 2011 Jan CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
 LEVETIRACETAM
 AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A 204312 001 Feb 01, 2016 Jan NEWA
 >D> TABLET; ORAL
 >D> SPRITAM
 >D> APRECIA PHARMS CO 250MG N 207958 001 Jul 31, 2015 Feb CDFR
 >D> 500MG N 207958 002 Jul 31, 2015 Feb CDFR
 >D> 750MG N 207958 003 Jul 31, 2015 Feb CDFR
 >D> 1GM N 207958 004 Jul 31, 2015 Feb CDFR
 TABLET, EXTENDED RELEASE; ORAL
 LEVETIRACETAM
 >A> AB INTELLIPHARMACEUTICS 500MG A 204511 001 Feb 23, 2016 Feb NEWA
 >A> AB 750MG A 204511 002 Feb 23, 2016 Feb NEWA
 >A> TABLET, FOR SUSPENSION; ORAL
 >A> SPRITAM
 >A> APRECIA PHARMS CO 250MG N 207958 001 Jul 31, 2015 Feb CDFR

>A> TABLET, FOR SUSPENSION;ORAL
 >A> SPRITAM
 >A> 500MG N207958 002 Jul 31, 2015 Feb CDFR
 >A> 750MG N207958 003 Jul 31, 2015 Feb CDFR
 >A> 1GM N207958 004 Jul 31, 2015 Feb CDFR

LEVOFLOXACIN

INJECTABLE;INJECTION
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
 AP AUROBINDO PHARMA LTD EQ 250MG/50ML (EQ 5MG/ML) A206919 001 Feb 10, 2016 Jan NEWA
 AP EQ 500MG/100ML (EQ 5MG/ML) A206919 002 Feb 10, 2016 Jan NEWA
 AP EQ 750MG/150ML (EQ 5MG/ML) A206919 003 Feb 10, 2016 Jan NEWA
 SOLUTION/DROPS;OPHTHALMIC
 LEVOFLOXACIN
 AT + RISING PHARMS INC 0.5% A077700 001 Dec 20, 2010 Jan CAHN

LIDOCAINE

OINTMENT;TOPICAL
 LIDOCAINE
 AT TELIGENT PHARMA INC 5% A205318 001 Feb 01, 2016 Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER
 >D> AP HOSPIRA 400MG/100ML N018388 002 Feb DISC
 >A> @ 400MG/100ML N018388 002 Feb DISC
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER
 >D> AP HOSPIRA 800MG/100ML N018388 003 Nov 05, 1982 Feb DISC
 >A> @ 800MG/100ML N018388 003 Nov 05, 1982 Feb DISC
 JELLY;TOPICAL
 ANESTACON
 @ BIONPHARMA INC 2% A080429 001 Jan CAHN

LINEZOLID

SOLUTION;IV (INFUSION)
 LINEZOLID
 >A> AP FRESENIUS KABI USA 600MG/300ML (2MG/ML) A204764 001 Mar 15, 2016 Feb NEWA
 TABLET;ORAL
 LINEZOLID
 AB GATE PHARMS 600MG A091210 001 Feb 05, 2016 Jan NEWA

LISINOPRIL

TABLET;ORAL
 ZESTRIL
 AB ALVOGEN MALTA 2.5MG N019777 005 Apr 29, 1993 Jan CAHN
 AB 5MG N019777 001 May 19, 1988 Jan CAHN
 AB 10MG N019777 002 May 19, 1988 Jan CAHN
 AB 20MG N019777 003 May 19, 1988 Jan CAHN
 AB 30MG N019777 006 Jan 20, 1999 Jan CAHN
 AB + 40MG N019777 004 May 19, 1988 Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL
 LITHIUM CARBONATE
 >A> AB DELCOR ASSET CORP 150MG A076243 002 Feb 24, 2003 Feb CAHN
 >A> AB 300MG A076243 001 Jun 27, 2002 Feb CAHN
 >A> AB 600MG A078763 001 Apr 15, 2008 Feb CAHN
 >D> AB HIKMA INTL PHARMS 150MG A076243 002 Feb 24, 2003 Feb CAHN
 >D> AB 300MG A076243 001 Jun 27, 2002 Feb CAHN
 >D> AB HIKMA PHARMS 600MG A078763 001 Apr 15, 2008 Feb CAHN
 AB 600MG A078763 001 Apr 15, 2008 Jan CMFD

LOMITAPIDE MESYLATE

CAPSULE;ORAL
 JUXTAPID
 AEGERION EQ 20MG BASE N203858 003 Dec 21, 2012 Jan CRLD
 + EQ 60MG BASE N203858 006 Apr 23, 2015 Jan CRLD

LOPERAMIDE HYDROCHLORIDE

		CAPSULE; ORAL							
>D>		IMODIUM							
>D>	AB	+	J AND J CONSUMER INC	2MG		N017694	001		Feb DISC
>A>			@	2MG		N017694	001		Feb DISC
		LOPERAMIDE HYDROCHLORIDE							
>D>	AB		MYLAN	2MG		A072741	001	Sep 18, 1991	Feb CRLD
>A>	AB	+		2MG		A072741	001	Sep 18, 1991	Feb CRLD

LOXAPINE

		POWDER; INHALATION							
		ADASUVE							
>A>		+	ALEXZA PHARMS	10MG		N022549	001	Dec 21, 2012	Feb CAHN
>D>		+	TEVA PHARMS USA INC	10MG		N022549	001	Dec 21, 2012	Feb CAHN

MAGNESIUM SULFATE

		INJECTABLE; INJECTION							
		MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
>A>	AP		FRESENIUS KABI USA	1GM/100ML		A206486	001	Mar 07, 2016	Feb NEWA
>D>		+	HOSPIRA	1GM/100ML		N020488	001	Jul 11, 1995	Feb CFTG
>A>	AP	+		1GM/100ML		N020488	001	Jul 11, 1995	Feb CFTG
>A>	AP		HQ SPCLT PHARMA	1GM/100ML		A207349	001	Mar 02, 2016	Feb NEWA
		MAGNESIUM SULFATE IN PLASTIC CONTAINER							
>A>	AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)		A206485	001	Mar 15, 2016	Feb NEWA
>A>	AP			4GM/50ML (80MG/ML)		A206485	002	Mar 15, 2016	Feb NEWA
>D>		+	HOSPIRA	4GM/100ML (40MG/ML)		N020309	001	Jun 24, 1994	Feb CFTG
>A>	AP	+		4GM/100ML (40MG/ML)		N020309	001	Jun 24, 1994	Feb CFTG
>D>		+		4GM/50ML (80MG/ML)		N020309	002	Jun 24, 1994	Feb CFTG
>A>	AP	+		4GM/50ML (80MG/ML)		N020309	002	Jun 24, 1994	Feb CFTG
		SOLUTION; INTRAMUSCULAR, INTRAVENOUS							
		MAGNESIUM SULFATE							
		+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)		N019316	003	Jan 29, 2016	Jan NEWA
		+		25GM/50ML (500MG/ML)		N019316	004	Jan 29, 2016	Jan NEWA

MECLIZINE HYDROCHLORIDE

		TABLET; ORAL							
		MECLIZINE HYDROCHLORIDE							
			@ RISING PHARMS INC	12.5MG		A040179	001	Jan 30, 1997	Jan CAHN
			@	25MG		A040179	002	Jan 30, 1997	Jan CAHN

MEGESTROL ACETATE

		SUSPENSION; ORAL							
		MEGACE ES							
>A>	AB	+	ENDO PHARMS INC	125MG/ML		N021778	001	Jul 05, 2005	Feb CAHN
>D>	AB	+	PAR PHARM	125MG/ML		N021778	001	Jul 05, 2005	Feb CAHN

MELOXICAM

		TABLET; ORAL							
		MELOXICAM							
			@ SUN PHARM INDS	7.5MG		A077935	001	Jul 19, 2006	Jan CAHN
			@	15MG		A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

		TABLET; ORAL							
		ALKERAN							
		+	APOTEX INC	2MG		N014691	002		Jan CAHN

MELPHALAN HYDROCHLORIDE

		INJECTABLE; INJECTION							
		ALKERAN							
AP		+	APOTEX INC	EQ 50MG BASE/VIAL		N020207	001	Nov 18, 1992	Jan CAHN

MEPERIDINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		DEMEROL							
			@ US PHARM HOLDINGS	25MG/ML		N005010	007		Jan CAHN
			@	50MG/ML		N005010	002		Jan CAHN
			@	75MG/ML		N005010	009		Jan CAHN
			@	100MG/ML		N005010	003		Jan CAHN

		SYRUP; ORAL							
		DEMEROL							
		@ US PHARM HOLDINGS	50MG/5ML		N005010	005			Jan CAHN
		TABLET; ORAL							
		DEMEROL							
AA	+	US PHARM HOLDINGS	50MG		N005010	001			Jan CAHN
AA	+		100MG		N005010	004			Jan CAHN
		<u>MEPROBAMATE</u>							
		TABLET; ORAL							
		MEPROBAMATE							
>A>		@ AUROLIFE PHARMA LLC	400MG		A080655	001			Feb CAHN
>D>		@ SANDOZ	400MG		A080655	001			Feb CAHN
		<u>MERCAPTOPURINE</u>							
		TABLET; ORAL							
		PURINETHOL							
		@ STASON PHARMS	50MG		N009053	002			Jan CAHN
		<u>MESALAMINE</u>							
		CAPSULE, DELAYED RELEASE; ORAL							
		DELZICOL							
	+	ALLERGAN PHARMS INTL	400MG		N204412	001	Feb 01, 2013		Jan CAHN
		TABLET, DELAYED RELEASE; ORAL							
		ASACOL							
		@ ALLERGAN PHARMS INTL	400MG		N019651	001	Jan 31, 1992		Jan CAHN
		ASACOL HD							
	+	ALLERGAN PHARMS INTL	800MG		N021830	001	May 29, 2008		Jan CAHN
		<u>METFORMIN HYDROCHLORIDE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		GLUMETZA							
AB3		SANTARUS INC	500MG		N021748	001	Jun 03, 2005		Jan CTEC
AB3	+		1GM		N021748	002	Jun 03, 2005		Jan CTEC
		<u>METHENAMINE HIPPURATE</u>							
		TABLET; ORAL							
		HIPREX							
AB	+	US PHARM HOLDINGS	1GM		N017681	001			Jan CAHN
		<u>METHIMAZOLE</u>							
		TABLET; ORAL							
		METHIMAZOLE							
AB		RISING PHARMS INC	5MG		A202068	001	Mar 07, 2012		Jan CAHN
AB			10MG		A202068	002	Mar 07, 2012		Jan CAHN
		<u>METHOCARBAMOL</u>							
		TABLET; ORAL							
		METHOCARBAMOL							
>D>	AA	SANDOZ	500MG		A084616	001			Feb DISC
>A>		@	500MG		A084616	001			Feb DISC
>D>	AA		750MG		A084615	001			Feb DISC
>A>		@	750MG		A084615	001			Feb DISC
		<u>METHOTREXATE SODIUM</u>							
		INJECTABLE; INJECTION							
		METHOTREXATE SODIUM PRESERVATIVE FREE							
AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)		A090039	001	Mar 31, 2009		Jan CAHN
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)		A090039	002	Mar 31, 2009		Jan CAHN
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)		A090029	001	Mar 31, 2009		Jan CAHN
		<u>METHYLERGONOVINE MALEATE</u>							
		TABLET; ORAL							
		METHERGINE							
		@ EDISON THERAPS LLC	0.2MG		N006035	003			Jan DISC
		METHYLERGONOVINE MALEATE							
	+	NOVEL LABS INC	0.2MG		A091577	001	May 02, 2011		Jan CRLD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
>A>	AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN
>D>	AA	SUN PHARM INDS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
>D>	AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb NEWA
>A>	AB		20MG	A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>A>	AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
>A>	AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
	AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
	AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
	AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
	AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
	AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

AB		NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan CAHN
AB			500MG	A070773	001	Jul 16, 1986	Jan CAHN

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+		MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan CAHN
---	--	--------------------	------	---------	-----	--------------	----------

MIGLITOL

TABLET;ORAL

GLYSET

>D>	AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CRLD
>A>	AB	+	25MG	N020682	001	Dec 18, 1996	Feb CRLD
>D>	AB	+	100MG	N020682	003	Dec 18, 1996	Feb CRLD
>A>	AB		100MG	N020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@		LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
			12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
@			25MG	A205071	002	Jan 27, 2016	Jan DISC
			25MG	A205071	002	Jan 27, 2016	Jan NEWA
@			50MG	A205071	003	Jan 27, 2016	Jan DISC
			50MG	A205071	003	Jan 27, 2016	Jan NEWA
@			100MG	A205071	004	Jan 27, 2016	Jan DISC
			100MG	A205071	004	Jan 27, 2016	Jan NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB			EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB			EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

@		ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
@			30MG	A076336	002	Jun 20, 2003	Jan DISC
@			45MG	A076336	003	Jun 20, 2003	Jan DISC

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINIL

TABLET; ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

>D>	AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
>A>	AB	+		10MG	N020616	008	Apr 20, 2007	Feb CTEC
>D>	AB1			20MG	N020616	001	Jul 03, 1996	Feb CTEC
>A>	AB			20MG	N020616	001	Jul 03, 1996	Feb CTEC
>D>	AB1			30MG	N020616	004	Mar 09, 2001	Feb CTEC
>A>	AB			30MG	N020616	004	Mar 09, 2001	Feb CTEC
>D>	AB1			40MG	N020616	009	Jul 09, 2012	Feb CTEC
>A>	AB			40MG	N020616	009	Jul 09, 2012	Feb CTEC
>D>	AB1			50MG	N020616	002	Jul 03, 1996	Feb CTEC
>A>	AB			50MG	N020616	002	Jul 03, 1996	Feb CTEC
>D>	AB1			60MG	N020616	005	Mar 09, 2001	Feb CTEC
>A>	AB			60MG	N020616	005	Mar 09, 2001	Feb CTEC
>D>	AB1			70MG	N020616	010	Jul 09, 2012	Feb CTEC
>A>	AB			70MG	N020616	010	Jul 09, 2012	Feb CTEC
>D>	AB1			80MG	N020616	006	Oct 27, 2006	Feb CTEC
>A>	AB			80MG	N020616	006	Oct 27, 2006	Feb CTEC
>D>	AB1	+		100MG	N020616	003	Jul 03, 1996	Feb CTEC
>A>	AB	+		100MG	N020616	003	Jul 03, 1996	Feb CTEC
>D>	AB1	+		200MG	N020616	007	Feb 27, 2007	Feb CTEC
>A>	AB	+		200MG	N020616	007	Feb 27, 2007	Feb CTEC

MORPHINE SULFATE

>D>	AB1		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
>A>	AB			20MG	A200812	001	Nov 10, 2011	Feb CTEC
>D>	AB1			30MG	A200812	002	Nov 10, 2011	Feb CTEC
>A>	AB			30MG	A200812	002	Nov 10, 2011	Feb CTEC
>D>	AB1			50MG	A200812	003	Nov 10, 2011	Feb CTEC
>A>	AB			50MG	A200812	003	Nov 10, 2011	Feb CTEC
>D>	AB1			60MG	A200812	004	Nov 10, 2011	Feb CTEC
>A>	AB			60MG	A200812	004	Nov 10, 2011	Feb CTEC
>D>	AB1			80MG	A200812	005	Nov 10, 2011	Feb CTEC
>A>	AB			80MG	A200812	005	Nov 10, 2011	Feb CTEC
>D>	AB1			100MG	A200812	006	Nov 10, 2011	Feb CTEC
>A>	AB			100MG	A200812	006	Nov 10, 2011	Feb CTEC
>D>	AB1		TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
>A>	AB			20MG	A202718	001	Dec 29, 2014	Feb CTEC
>D>	AB1			30MG	A202718	002	Dec 29, 2014	Feb CTEC
>A>	AB			30MG	A202718	002	Dec 29, 2014	Feb CTEC
>D>	AB1			40MG	A202718	007	Jun 03, 2015	Feb CTEC
>A>	AB			40MG	A202718	007	Jun 03, 2015	Feb CTEC
>D>	AB1			50MG	A202718	003	Dec 29, 2014	Feb CTEC
>A>	AB			50MG	A202718	003	Dec 29, 2014	Feb CTEC
>D>	AB1			60MG	A202718	004	Dec 29, 2014	Feb CTEC
>A>	AB			60MG	A202718	004	Dec 29, 2014	Feb CTEC
>D>	AB1			70MG	A202718	008	Jun 03, 2015	Feb CTEC
>A>	AB			70MG	A202718	008	Jun 03, 2015	Feb CTEC
>D>	AB1			80MG	A202718	005	Dec 29, 2014	Feb CTEC
>A>	AB			80MG	A202718	005	Dec 29, 2014	Feb CTEC
>D>	AB1			100MG	A202718	006	Dec 29, 2014	Feb CTEC
>A>	AB			100MG	A202718	006	Dec 29, 2014	Feb CTEC
>D>	AB1		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
>A>	AB			10MG	A202104	001	Jun 03, 2013	Feb CTEC
>D>	AB1			20MG	A202104	002	Jun 03, 2013	Feb CTEC
>A>	AB			20MG	A202104	002	Jun 03, 2013	Feb CTEC
>D>	AB1			30MG	A202104	003	Jun 03, 2013	Feb CTEC
>A>	AB			30MG	A202104	003	Jun 03, 2013	Feb CTEC
>D>	AB1			50MG	A202104	004	Jun 03, 2013	Feb CTEC
>A>	AB			50MG	A202104	004	Jun 03, 2013	Feb CTEC

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>D>	AB1		60MG	A202104	005	Jun 03, 2013	Feb	CTEC
>A>	AB		60MG	A202104	005	Jun 03, 2013	Feb	CTEC
>D>	AB1		80MG	A202104	006	Jun 03, 2013	Feb	CTEC
>A>	AB		80MG	A202104	006	Jun 03, 2013	Feb	CTEC
>D>	AB1		100MG	A202104	007	Jun 03, 2013	Feb	CTEC
>A>	AB		100MG	A202104	007	Jun 03, 2013	Feb	CTEC

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL
MOXIFLOXACIN HYDROCHLORIDE

AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

NAPROXEN

TABLET;ORAL
NAPROSYN

>A>	AB	ATNAHS PHARMA US	250MG	N017581	002		Feb	CAHN
>A>	AB		375MG	N017581	003		Feb	CAHN
>A>	AB	+	500MG	N017581	004	Apr 15, 1982	Feb	CAHN
>D>	AB	ROCHE PALO	250MG	N017581	002		Feb	CAHN
>D>	AB		375MG	N017581	003		Feb	CAHN
>D>	AB	+	500MG	N017581	004	Apr 15, 1982	Feb	CAHN
NAPROXEN								
>D>	AB	SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb	DISC
>A>		@	250MG	A074140	001	Dec 21, 1993	Feb	DISC
>D>	AB		375MG	A074140	002	Dec 21, 1993	Feb	DISC
>A>		@	375MG	A074140	002	Dec 21, 1993	Feb	DISC
>D>	AB		500MG	A074140	003	Dec 21, 1993	Feb	DISC
>A>		@	500MG	A074140	003	Dec 21, 1993	Feb	DISC

TABLET, DELAYED RELEASE;ORAL
EC-NAPROSYN

>A>	AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb	CAHN
>A>	AB	+		500MG	N020067	003	Oct 14, 1994	Feb	CAHN
>D>	AB	+	ROCHE PALO	375MG	N020067	002	Oct 14, 1994	Feb	CAHN
>D>	AB	+		500MG	N020067	003	Oct 14, 1994	Feb	CAHN
NAPROXEN									
>D>	AB	SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb	DISC	
>A>		@	375MG	A075061	001	Feb 18, 1998	Feb	DISC	
>D>	AB		500MG	A075061	002	Feb 18, 1998	Feb	DISC	
>A>		@	500MG	A075061	002	Feb 18, 1998	Feb	DISC	

NAPROXEN SODIUM

TABLET;ORAL
ANAPROX

>A>	AB	ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb	CAHN	
>D>	AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164	001		Feb	CAHN	
ANAPROX DS									
>A>	AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb	CAHN
>D>	AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb	DISC
>A>		@	50MG	A076409	001	Sep 16, 2003	Feb	DISC
>D>	AB		100MG	A076409	002	Sep 16, 2003	Feb	DISC
>A>		@	100MG	A076409	002	Sep 16, 2003	Feb	DISC
>D>	AB		150MG	A076409	003	Sep 16, 2003	Feb	DISC
>A>		@	150MG	A076409	003	Sep 16, 2003	Feb	DISC
>D>	AB		200MG	A076409	004	Sep 16, 2003	Feb	DISC
>A>		@	200MG	A076409	004	Sep 16, 2003	Feb	DISC
>D>	AB		250MG	A076409	005	Sep 16, 2003	Feb	DISC
>A>		@	250MG	A076409	005	Sep 16, 2003	Feb	DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
ADALAT CC

>A>	AB1	ALVOGEN	30MG	N020198	001	Apr 21, 1993	Feb	CAHN
>A>	AB1	+	60MG	N020198	002	Apr 21, 1993	Feb	CAHN
>A>	AB1	+	90MG	N020198	003	Apr 21, 1993	Feb	CAHN
>D>	AB1	BAYER HLTHCARE	30MG	N020198	001	Apr 21, 1993	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL									
ADALAT CC									
>D>	AB1	+		60MG		N020198	002	Apr 21, 1993	Feb CAHN
>D>	AB1	+		90MG		N020198	003	Apr 21, 1993	Feb CAHN
NIFEDIPINE									
	AB1		VALEANT PHARMS NORTH	30MG		A075269	001	Dec 04, 2000	Jan CAHN
	AB1			60MG		A075269	002	Dec 04, 2000	Jan CAHN
	AB1			90MG		A076070	001	Aug 16, 2002	Jan CAHN
<u>NIMODIPINE</u>									
CAPSULE;ORAL									
NIMODIPINE									
AB	+		BIONPHARMA INC	30MG		A076740	001	Jan 17, 2008	Jan CAHN
<u>NITRIC OXIDE</u>									
GAS;INHALATION									
INOMAX									
	+		MALLINCKRODT HOSP	800PPM		N020845	003	Dec 23, 1999	Jan CAHN
<u>NITROFURANTOIN</u>									
SUSPENSION;ORAL									
NITROFURANTOIN									
>A>	AB		NOSTRUM LABS INC	25MG/5ML		A201355	001	Aug 14, 2013	Feb CAHN
>D>	AB		SUN PHARM INDS INC	25MG/5ML		A201355	001	Aug 14, 2013	Feb CAHN
<u>NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE;ORAL									
NITROFURANTOIN									
>A>	AB		SUN PHARM INDS	25MG		A201722	001	Feb 16, 2016	Feb NEWA
>A>	AB			50MG		A201722	002	Feb 16, 2016	Feb NEWA
>A>	AB			100MG		A201722	003	Feb 16, 2016	Feb NEWA
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE;ORAL									
MACROBID									
AB	+		ALVOGEN MALTA	75MG;25MG		N020064	001	Dec 24, 1991	Jan CAHN
<u>NIZATIDINE</u>									
SOLUTION;ORAL									
AXID									
>D>	AA	+	BRAINTREE	15MG/ML		N021494	001	May 25, 2004	Feb DISC
>A>		@		15MG/ML		N021494	001	May 25, 2004	Feb DISC
NIZATIDINE									
>D>	AA		AMNEAL PHARMS	15MG/ML		A090576	001	Nov 18, 2009	Feb CRLD
>A>		+		15MG/ML		A090576	001	Nov 18, 2009	Feb CRLD
<u>NOREPINEPHRINE BITARTRATE</u>									
INJECTABLE;INJECTION									
NOREPINEPHRINE BITARTRATE									
AP			CLARIS	EQ 1MG BASE/ML		A040859	001	Mar 27, 2012	Jan CAHN
<u>NORETHINDRONE</u>									
TABLET;ORAL-28									
NOR-QD									
AB1	+		ALLERGAN PHARMS INTL	0.35MG		N017060	001		Jan CAHN
<u>NORTRIPTYLINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
NORTRIPTYLINE HYDROCHLORIDE									
>A>		@	AUROLIFE PHARMA LLC	EQ 10MG BASE		A074835	001	Jun 30, 1997	Feb CAHN
>A>		@		EQ 25MG BASE		A074835	002	Jun 30, 1997	Feb CAHN
>A>		@		EQ 50MG BASE		A074835	003	Jun 30, 1997	Feb CAHN
>A>		@		EQ 75MG BASE		A074835	004	Jun 30, 1997	Feb CAHN
>D>		@	SANDOZ	EQ 10MG BASE		A074835	001	Jun 30, 1997	Feb CAHN
>D>		@		EQ 25MG BASE		A074835	002	Jun 30, 1997	Feb CAHN
>D>		@		EQ 50MG BASE		A074835	003	Jun 30, 1997	Feb CAHN
>D>		@		EQ 75MG BASE		A074835	004	Jun 30, 1997	Feb CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

	@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan	DISC
	@		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan	DISC
			OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
>D>	@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb	CMS1
	@		EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan	DISC
>D>	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb	CMS1
	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan	DISC
>D>	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb	CMS1
	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan	DISC
			OCTREOTIDE ACETATE PRESERVATIVE FREE					
>A>	@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb	CMS1
>A>	@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb	CMS1
>A>	@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb	CMS1

OFLOXACIN

SOLUTION/DROPS; OTIC

FLOXIN OTIC

>D>	AT	+	DAIICHI	0.3%	N020799	001	Dec 16, 1997	Feb	DISC
>A>		@		0.3%	N020799	001	Dec 16, 1997	Feb	DISC
			OFLOXACIN						
>D>	AT		BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb	CRLD
>A>	AT	+		0.3%	A076128	001	Mar 17, 2008	Feb	CRLD

OLANZAPINE

TABLET; ORAL

OLANZAPINE

>A>	AB		INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb	NEWA
>A>	AB			5MG	A203333	002	Mar 15, 2016	Feb	NEWA
>A>	AB			7.5MG	A203333	003	Mar 15, 2016	Feb	NEWA
>A>	AB			10MG	A203333	004	Mar 15, 2016	Feb	NEWA
>A>	AB			15MG	A203333	005	Mar 15, 2016	Feb	NEWA
>A>	AB			20MG	A203333	006	Mar 15, 2016	Feb	NEWA
	AB		QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan	NEWA
	AB			5MG	A204319	002	Jan 27, 2016	Jan	NEWA
	AB			7.5MG	A204319	003	Jan 27, 2016	Jan	NEWA
	AB			10MG	A204319	004	Jan 27, 2016	Jan	NEWA
	AB			15MG	A204319	005	Jan 27, 2016	Jan	NEWA
	AB			20MG	A204319	006	Jan 27, 2016	Jan	NEWA
			TABLET, ORALLY DISINTEGRATING; ORAL						
			OLANZAPINE						
>A>	AB		INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb	NEWA
>A>	AB			10MG	A203456	002	Mar 16, 2016	Feb	NEWA
>A>	AB			15MG	A203456	003	Mar 16, 2016	Feb	NEWA
>A>	AB			20MG	A203456	004	Mar 16, 2016	Feb	NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB			AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan	CMS1
----	--	--	---------------	--	---------	-----	--------------	-----	------

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>A>	AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb	NEWA
-----	----	--	-----------------	----------------	---------	-----	--------------	-----	------

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP			SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan	CAHN
AP				100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan	CAHN

OXICONAZOLE NITRATE

CREAM;TOPICAL

>A>		OXICONAZOLE NITRATE						
>A>	AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb	NEWA
		OXISTAT						
>D>		+ FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb	CFTG
>A>	AB	+	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb	CFTG

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

>A>	AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb	NEWA
>A>	AB		10MG	A207138	002	Feb 29, 2016	Feb	NEWA
>A>	AB		15MG	A207138	003	Feb 29, 2016	Feb	NEWA

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan	CAHN
AB			15MG	A202116	002	Dec 30, 2011	Jan	CAHN
AB			30MG	A202116	003	Dec 30, 2011	Jan	CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP		SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan	CAHN
----	--	------------	--------	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
AP			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA
AB			EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB			2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB			4MCG	A202539	003	Mar 27, 2014	Jan	CAHN
>A>	AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA
>A>	AB		2MCG	A206710	002	Feb 24, 2016	Feb	NEWA
>A>	AB		4MCG	A206710	003	Feb 24, 2016	Feb	NEWA

SOLUTION;INTRAVENOUS

PARICALCITOL

>A>	AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA
>A>	AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb	NEWA
>A>	AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb	NEWA

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

>A>		@ HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb	CAHN
>D>		@ HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb	CAHN

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

>A>		@ HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb	CAHN
>D>		@ HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
TRENENTAL

@ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Jan CAHN

PERPHENAZINE

TABLET;ORAL
PERPHENAZINE

AB WILSHIRE PHARMS INC 2MG A205973 001 Dec 17, 2015 Jan CAHN
 AB 4MG A205973 002 Dec 17, 2015 Jan CAHN
 AB 8MG A205973 003 Dec 17, 2015 Jan CAHN
 AB 16MG A205973 004 Dec 17, 2015 Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@ ABLE 200MG,N/A,N/A;N/A,800MG,160MG N021105 001 Jun 26, 2001 Jan CMS1

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL
PHENTERMINE HYDROCHLORIDE

AA INGENUS PHARMS NJ 37.5MG A091451 001 Sep 21, 2012 Jan CAHN

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON

@ TELIGENT PHARMA INC 1MG/0.5ML N012223 002 Jan CAHN
 @ 10MG/ML N012223 001 Jan CAHN

PIROXICAM

CAPSULE;ORAL
PIROXICAM

AB MYLAN PHARMS INC 20MG A074118 001 Jun 15, 1993 Jan CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB GLENMARK PHARMS LTD 10MEQ A202868 001 Jan 19, 2016 Jan NEWA
 >A> AB TRIS PHARMA INC 8MEQ A201944 001 Mar 04, 2016 Feb NEWA
 >A> AB 10MEQ A201944 002 Mar 04, 2016 Feb NEWA
 TABLET, EXTENDED RELEASE;ORAL
 POTASSIUM CHLORIDE
 AB1 NOVEL LABS INC 10MEQ A206347 001 Jan 21, 2016 Jan NEWA
 AB1 20MEQ A206347 002 Jan 21, 2016 Jan NEWA

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE

>A> @ AUROLIFE PHARMA LLC 5MG A084773 001 Feb CAHN
 >D> @ SANDOZ 5MG A084773 001 Feb CAHN

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB BIONPHARMA INC 100MG A200900 001 Aug 16, 2013 Jan CAHN
 AB 200MG A200900 002 Aug 16, 2013 Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

>A> AA NOSTRUM LABS INC 6.25MG/5ML A040891 001 Mar 13, 2009 Feb CAHN
 >D> AA SUN PHARM INDS INC 6.25MG/5ML A040891 001 Mar 13, 2009 Feb CAHN

TABLET;ORAL
PROMETHAZINE HYDROCHLORIDE

@ SUN PHARM INDS 50MG A084557 001 Jan CAHN

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB ALVOGEN MALTA 180MG A204737 001 Jun 26, 2015 Jan CAHN

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE

>A> AB UNICHEM LABS LTD EQ 25MG BASE A202674 001 Mar 08, 2016 Feb NEWA
>A> AB EQ 50MG BASE A202674 002 Mar 08, 2016 Feb NEWA
>A> AB EQ 100MG BASE A202674 003 Mar 08, 2016 Feb NEWA
>A> AB EQ 200MG BASE A202674 004 Mar 08, 2016 Feb NEWA
>A> AB EQ 300MG BASE A202674 005 Mar 08, 2016 Feb NEWA
>A> AB EQ 400MG BASE A202674 006 Mar 08, 2016 Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL
QUINAPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC EQ 5MG BASE A076049 001 Jan 14, 2005 Jan DISC
@ EQ 10MG BASE A076049 002 Jan 14, 2005 Jan DISC
@ EQ 20MG BASE A076049 003 Jan 14, 2005 Jan DISC
@ EQ 40MG BASE A076049 004 Jan 14, 2005 Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
ZANTAC

AP + IGI LABS INC EQ 25MG BASE/ML N019090 001 Oct 19, 1984 Jan CAHN
ZANTAC IN PLASTIC CONTAINER
@ IGI LABS INC EQ 1MG BASE/ML N019593 002 Sep 27, 1991 Jan CAHN
@ EQ 50MG BASE/100ML N019593 001 Dec 17, 1986 Jan CAHN

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

>A> AB ORCHID HLTHCARE EQ 0.5MG BASE A201970 001 Mar 15, 2016 Feb NEWA
>A> AB EQ 1MG BASE A201970 002 Mar 15, 2016 Feb NEWA

RESERPINE

TABLET;ORAL
RESERPINE

>A> @ HIKMA INTL PHARMS 0.1MG A080975 001 Feb CAHN
>A> @ 0.25MG A080975 002 Feb CAHN
>A> @ 1MG A080975 003 Feb CAHN
>D> @ HIKMA PHARMS LLC 0.1MG A080975 001 Feb CAHN
>D> @ 0.25MG A080975 002 Feb CAHN
>D> @ 1MG A080975 003 Feb CAHN

RETAPAMULIN

OINTMENT;TOPICAL
ALTABAX

+ AQUA PHARMS LLC 1% N022055 001 Apr 12, 2007 Jan CAHN

RIFAMPIN

INJECTABLE;INJECTION
RIFAMPIN

>A> AP HIKMA PHARMS 600MG/VIAL A205039 001 Mar 03, 2016 Feb NEWA
AP WATSON PHARMS INC 600MG/VIAL A206736 001 Jan 19, 2016 Jan NEWA

RISEDRONATE SODIUM

TABLET;ORAL
ACTONEL

AB ALLERGAN PHARMS INTL 5MG N020835 002 Apr 14, 2000 Jan CAHN
AB 30MG N020835 001 Mar 27, 1998 Jan CAHN
AB + 35MG N020835 003 May 25, 2002 Jan CAHN
@ 75MG N020835 004 Apr 16, 2007 Jan CAHN
AB + 150MG N020835 005 Apr 22, 2008 Jan CAHN
TABLET, DELAYED RELEASE;ORAL
ATELVIA
AB + ALLERGAN PHARMS INTL 35MG N022560 001 Oct 08, 2010 Jan CAHN

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATECAPSULE;ORAL
EXELON

AB	+ NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD
----	------------	-------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATETABLET;ORAL
RIZATRIPTAN BENZOATE

>A>	AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
>A>	AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
	AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
	AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

SILDENAFIL CITRATETABLET;ORAL
SILDENAFIL CITRATE

>A>	@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb DISC
>A>			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb NEWA
>A>	@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb DISC
>A>			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb NEWA
>A>	@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb DISC
>A>			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb NEWA

SIMVASTATINTABLET;ORAL
SIMVASTATIN

>D>	AB	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb DISC
>A>	@		5MG	A076285	001	Dec 20, 2006	Feb DISC
>D>	AB		10MG	A076285	002	Dec 20, 2006	Feb DISC
>A>	@		10MG	A076285	002	Dec 20, 2006	Feb DISC
>D>	AB		20MG	A076285	003	Dec 20, 2006	Feb DISC
>A>	@		20MG	A076285	003	Dec 20, 2006	Feb DISC
>D>	AB		40MG	A076285	004	Dec 20, 2006	Feb DISC
>A>	@		40MG	A076285	004	Dec 20, 2006	Feb DISC
>D>	AB		80MG	A076285	005	Jun 23, 2006	Feb DISC
>A>	@		80MG	A076285	005	Jun 23, 2006	Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION;IV (INFUSION)
AMMONUL

>D>	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
>A>	AP		10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
>A>	AP	AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb NEWA

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

>A>		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb NEWA
-----	--	-------------	-----------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

>D>	AP	IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN
>A>	AP	ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

>A>	AA	BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
>A>	AA	INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA

SUCRALFATE

TABLET; ORAL
 SUCRALFATE
 AB MYLAN IRELAND LTD 1GM A074415 001 Jun 08, 1998 Jan CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS
 BRIDION
 ORGANON SUB MERCK EQ 200MG BASE/2ML (EQ 100MG BASE/ML) N022225 002 Dec 15, 2015 Jan CPOT
 + EQ 500MG BASE/5ML (EQ 100MG BASE/ML) N022225 001 Dec 15, 2015 Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL
 SULFAMETHOXAZOLE
 >A> @ AUROLIFE PHARMA LLC 500MG A085844 001 Feb CAHN
 >D> @ SANDOZ 500MG A085844 001 Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
 SULFAMETHOXAZOLE AND TRIMETHOPRIM
 @ ANI PHARMS INC 200MG/5ML; 40MG/5ML A077612 001 Nov 13, 2006 Jan CAHN

SULFISOXAZOLE

TABLET; ORAL
 SULFISOXAZOLE
 >A> @ AUROLIFE PHARMA LLC 500MG A085628 001 Feb CAHN
 >D> @ SANDOZ 500MG A085628 001 Feb CAHN

SUMATRIPTAN

SPRAY; NASAL
 IMITREX
 >D> + GLAXOSMITHKLINE 5MG/SPRAY N020626 001 Aug 26, 1997 Feb CFTG
 >A> AB + 5MG/SPRAY N020626 001 Aug 26, 1997 Feb CFTG
 >D> + 20MG/SPRAY N020626 003 Aug 26, 1997 Feb CFTG
 >A> AB + 20MG/SPRAY N020626 003 Aug 26, 1997 Feb CFTG
 >A> SUMATRIPTAN
 >A> AB LANNETT 5MG/SPRAY A204841 001 Feb 19, 2016 Feb NEWA
 >A> AB 20MG/SPRAY A204841 002 Feb 19, 2016 Feb NEWA

SUMATRIPTAN SUCCINATE

POWDER; INHALATION
 ONZETRA XSAIL
 + AVANIR PHARMS EQ 11MG BASE N206099 001 Jan 27, 2016 Jan NEWA
 SOLUTION; SUBCUTANEOUS
 ZEMBRACE SYMTOUCH
 DR REDDYS LABS LTD EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N208223 001 Jan 28, 2016 Jan NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL
 SOLTAMOX
 MIDATECH PHARMA US EQ 10MG BASE/5ML N021807 001 Oct 29, 2005 Jan CAHN
 TABLET; ORAL
 TAMOXIFEN CITRATE
 @ ACTAVIS LABS FL INC EQ 10MG BASE A076179 001 Feb 20, 2003 Jan DISC
 @ EQ 20MG BASE A076179 002 Feb 20, 2003 Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS
 ULTRA-TECHNEKOW FM
 + MALLINKRODT NUCLEAR 1-19 CI/GENERATOR N017243 003 Feb 18, 2014 Jan CAHN
 @ 0.25-3 CI/GENERATOR N017243 002 Jan CAHN

TEGASEROD MALEATE

TABLET; ORAL
 ZELNORM
 @ US WORLDMEDS LLC EQ 2MG BASE N021200 001 Jul 24, 2002 Jan CAHN
 @ EQ 6MG BASE N021200 002 Jul 24, 2002 Jan CAHN

TEMOZOLOMIDE

	CAPSULE;ORAL							
	TEMOZOLOMIDE							
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA	
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA	
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA	
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA	
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA	
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA	

TETRABENAZINE

	TABLET;ORAL							
	TETRABENAZINE							
AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA	
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA	

TETRACAINE HYDROCHLORIDE

>A>	SOLUTION;OPHTHALMIC							
>A>	TETRACAINE HYDROCHLORIDE							
>A>	+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb	NEWA

THEOPHYLLINE

	SOLUTION, ELIXIR;ORAL							
	ELIXOPHYLLIN							
	+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan	CAHN
	TABLET, EXTENDED RELEASE;ORAL							
	THEOCHRON							
AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan	CAHN	
AB		200MG	A088321	001	Feb 21, 1985	Jan	CAHN	
	@		300MG	A087400	002	Jan 11, 1983	Jan	CAHN
	THEOPHYLLINE							
AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan	CAHN	
AB	+		600MG	A040560	002	Apr 21, 2006	Jan	CAHN

TOFACITINIB CITRATE

>A>	TABLET, EXTENDED RELEASE;ORAL							
>A>	XELJANZ XR							
>A>	+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA

TOPIRAMATE

	TABLET;ORAL							
	TOPIRAMATE							
AB	ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Jan	CAHN	
AB		50MG	A078637	002	Feb 27, 2013	Jan	CAHN	
AB		100MG	A078637	003	Feb 27, 2013	Jan	CAHN	
AB		200MG	A078637	004	Feb 27, 2013	Jan	CAHN	

TRANEXAMIC ACID

	INJECTABLE;INJECTION							
	TRANEXAMIC ACID							
AP	AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan	NEWA	
>A> AP	NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb	NEWA	

TRAZODONE HYDROCHLORIDE

	TABLET;ORAL							
	TRAZODONE HYDROCHLORIDE							
>A>	@	AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb	CAHN
>D>	@	SANDOZ	50MG	A072484	001	Apr 30, 1990	Feb	CAHN

TRETINOIN

	CREAM;TOPICAL							
	TRETINOIN							
>A> AB	ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb	CAHN	
>A> AB1		0.05%	A075265	001	Dec 24, 1998	Feb	CAHN	
>A> AB		0.1%	A075213	001	Dec 24, 1998	Feb	CAHN	
>D> AB	MATAWAN PHARMS	0.025%	A075264	001	Dec 24, 1998	Feb	CAHN	
>D> AB1		0.05%	A075265	001	Dec 24, 1998	Feb	CAHN	
>D> AB		0.1%	A075213	001	Dec 24, 1998	Feb	CAHN	

GEL; TOPICAL

TRETINOIN

>A>	AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
>A>	AB		0.025%	A075529	001	Feb 22, 2000	Feb	CAHN
>D>	AB	MATAWAN PHARMS	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
>D>	AB		0.025%	A075529	001	Feb 22, 2000	Feb	CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

		@ AYTU PHARMS	EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995	Jan	CAHN
		+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan	CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB		BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan	CAHN
		CAPSULE, DELAYED RELEASE; ORAL						
		STAVZOR						
		@ BIONPHARMA INC	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
		@	250MG	N022152	002	Jul 29, 2008	Jan	CAHN
		@	500MG	N022152	003	Jul 29, 2008	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP		SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan	CAHN
AP			20MG/VIAL	A078274	002	Dec 29, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

>D>	AB	+	PFIZER	180MG	N019152	002	Dec 15, 1989	Feb	DISC
>A>		@		180MG	N019152	002	Dec 15, 1989	Feb	DISC

VORICONAZOLE

TABLET; ORAL

VORICONAZOLE

AB		AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA
AB			200MG	A206837	002	Jan 22, 2016	Jan	NEWA

XENON XE-133

GAS; INHALATION

XENON XE 133

>D>	AA		LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC
>A>				20mCi/VIAL	N017284	002		Feb	CTEC
>D>		@	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
>A>				10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
>D>		@		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD
>A>				20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

>D>	AB		EISAI INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
>D>	AB			50MG	N020789	002	Aug 22, 2003	Feb	CAHN
>D>	AB	+		100MG	N020789	001	Mar 27, 2000	Feb	CAHN
>A>	AB		SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
>A>	AB			50MG	N020789	002	Aug 22, 2003	Feb	CAHN
>A>	AB	+		100MG	N020789	001	Mar 27, 2000	Feb	CAHN
			ZONISAMIDE						
AB			BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB				50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB				100MG	A077813	003	Aug 16, 2006	Jan	CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

>A>	+	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Feb CAHN
>D>	+	NOVARTIS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Feb CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

		BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan CAHN
	+		10MG	N022429	004	Jul 23, 2009	Jan CAHN
		CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
		BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan CAHN
	+		10MG	N022429	002	Jul 23, 2009	Jan CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>		NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb NEWA
>A>			10MG	A206793	002	Mar 08, 2016	Feb NEWA

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

>A>	@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb CAHN
>D>	@	SANDOZ	12MG	A070797	001	Aug 12, 1988	Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

		BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN
--	--	----------------	--	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

>A>		APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb NEWA
-----	--	---------------------	--------------	---------	-----	--------------	----------

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

		BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
--	--	----------------	---------------------------------------	---------	-----	--------------	----------

MIDOL LIQUID GELS

	+	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002	Jan CAHN
--	---	----------------	-------	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

HER STYLE

>A>		NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb NEWA
-----	--	-----------------	-------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

		BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan CAHN
	+		2MG	N021855	002	Aug 04, 2005	Jan CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

>A>		ACTAVIS LABS NY INC	EQ 4MG BASE	A204833	001	Feb 26, 2016	Feb NEWA
-----	--	---------------------	-------------	---------	-----	--------------	----------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

	+	ALLERGAN SALES LLC	3.9MG/24HR	N202211	001	Jan 25, 2013	Jan CAHN
--	---	--------------------	------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2016

NO FEBRUARY 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	>A> 9242986	Oct 08, 2029	DS DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001				>A> ODE		Dec 11, 2022
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	>A> 8709491	Jun 28, 2032	DP			
	>A> 8840924	Jun 05, 2026	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	>A> 8709491	Jun 28, 2032	DP			
	>A> 8840924	Jun 05, 2026	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	>A> 8709491	Jun 28, 2032	DP			
	>A> 8840924	Jun 05, 2026	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	>A> 8709491	Jun 28, 2032	DP			
	>A> 8840924	Jun 05, 2026	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	>A> 8709491	Jun 28, 2032	DP			
	>A> 8840924	Jun 05, 2026	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	>A> 8709491	Jun 28, 2032	DP			
	>A> 8840924	Jun 05, 2026	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	>A> 9259428	Jun 13, 2023	U-644			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	>A> 9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	>A> 9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	>A> 9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001				>A> NDF		Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	>A> 9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	>A> 6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 8492416	Feb 21, 2021	U-1815			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 9192576	Apr 30, 2032	DP U-976			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	>A> 9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	>A> 9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	>A> 9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	>A> 9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	>A> 9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	>A> 9248123	Jan 13, 2032	U-1808			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-722 I-723	Jan 21, 2019 Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	>A> 7803788	Feb 02, 2022	U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					>A> ODE	Nov 10, 2022
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	>A> 9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	>A> 9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					>A> D-161 >A> D-162 >A> I-726 >A> I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					>A> D-161 >A> D-162 >A> I-726 >A> I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002				>A> D-161	Feb 05, 2019
					>A> D-162	Feb 05, 2019
					>A> I-726	Feb 05, 2019
					>A> I-727	Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001				D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154	001	>A> 5863560	Sep 11, 2016	DP	>A> NS	Feb 24, 2019
		>A> 6060085	Sep 11, 2016	U-124		
		>A> 6620435	Sep 11, 2016	DP		
		>A> 9161926	Nov 18, 2033	DP		
<u>DEFERASIROX - JADENU</u>						
N 206910	001				ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910	002				ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910	003				ODE	Jan 23, 2020
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818	001	>A> 8450287	Dec 19, 2027	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	001	>A> 9233103	Mar 05, 2032	U-1805		
		>A> 9238029	Jan 17, 2026	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	002	>A> 9233103	Mar 05, 2032	U-1805		
		>A> 9238029	Jan 17, 2026	DP		
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056	001	>A> 6238994	May 17, 2019	DP		
		>A> 6238994*PED	Nov 17, 2019			
		>A> 6462058	Jun 15, 2020	DS DP	U-950	
		>A> 6462058	Jun 15, 2020	DS DP	U-951	
		>A> 6462058*PED	Dec 15, 2020			
		>A> 6664276	Jan 30, 2023	DS DP	U-950	
		>A> 6664276	Jan 30, 2023	DS DP	U-951	
		>A> 6664276*PED	Jul 30, 2023			
		>A> 6939971	Jun 15, 2020		U-950	
		>A> 6939971	Jun 15, 2020		U-951	
		>A> 6939971*PED	Dec 15, 2020			
		>A> 7285668	Jun 15, 2020	DS		
		>A> 7285668*PED	Dec 15, 2020			
		>A> 7399485	May 26, 2018	DP		
		>A> 7399485*PED	Nov 26, 2018			
		>A> 7431942	May 17, 2019	DP		
		>A> 7431942*PED	Nov 17, 2019			
		>A> 7875292	May 17, 2019	DP		
		>A> 7875292*PED	Nov 17, 2019			
		>A> 8461187	Jan 17, 2026	DP		
		>A> 8461187*PED	Jul 17, 2026			
		>A> 8784885	Oct 15, 2023	DP		
		>A> 8784885*PED	Apr 15, 2024			
		>A> 8871273	Jan 11, 2028	DP		
		>A> 8871273*PED	Jul 11, 2028			
		>A> 9011926	Feb 24, 2026	DP		
		>A> 9145389	Jun 15, 2020	DS DP		
		>A> 9238029	Jan 17, 2026	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	>A> 9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	>A> 9107898	May 01, 2028	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	>A> 9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>ELBASVIR; GRAZOPREVRIR - ZEPATIER</u>						
N 208261 001	>A> 7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	>A> 8871759	May 04, 2031	DS DP U-1813			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 8551957	Oct 19, 2029	DP U-1651			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 8551957	Oct 19, 2029	DP U-1651			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 7407955	May 02, 2025	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 7407955	May 02, 2025	DS DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	>A> 9238108	Jan 22, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	>A> 9238108	Jan 22, 2027	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	>A> 6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	>A> 6469182	Jun 16, 2019	U-1812		>A> ODE	Jan 28, 2023
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031	U-1781			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	>A> 8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A> 8410131*PED	May 01, 2026				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	>A> 8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A> 8410131*PED	May 01, 2026				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	>A> 8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A> 8410131*PED	May 01, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	>A> 8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A> 8410131*PED	May 01, 2026				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	>A> 9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 9238076	Apr 15, 2024	DP U-412			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	>A> 9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	>A> 9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	>A> 9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	>A> 9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	>A> 9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	>A> 9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	>A> 9241935	Jan 25, 2027	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					>A> D-155	Feb 01, 2019
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	>A> 5968979	Jul 28, 2018	DS DP U-1378			
	>A> 9254278	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	>A> 6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	>A> 7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					>A> NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	>A> 9265760	Jul 23, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	>A> 9265760	Jul 23, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	>A> 9265760	Jul 23, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	>A> 9265760	Jul 23, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	>A> 9265760	Jul 23, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	>A> 9265760	Jul 23, 2033	U-1810			
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	>A> RE43932	Jul 16, 2018	DS DP			
	>A> RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	>A> RE43932	Jul 16, 2018	DS DP			
	>A> RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	>A> 7544799	Jul 16, 2018	DS DP	Y		
	>A> 7544799*PED	Jan 16, 2019				
	>A> RE43932	Jul 16, 2018	DS DP			
	>A> RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	>A> 7544799	Jul 16, 2018	DS DP	Y		
	>A> 7544799*PED	Jan 16, 2019				
	>A> RE43932	Jul 16, 2018	DS DP			
	>A> RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	>A> 6878721	Feb 25, 2025	DS DP U-1168			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9233211	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9233211	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001					ODE	Oct 22, 2022
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	>A> 9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778	>A> ODE		Nov 20, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		>A> ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		>A> ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	>A> 9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	>A> 9278101	Jul 30, 2023	U-1518			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					>A> D-158 >A> D-159 >A> D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	>A> 9216179	Aug 02, 2030		U-1806		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	>A> 7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	>A> 7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	>A> 7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 7407955	May 02, 2025	DS DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	>A> 9265893	Sep 23, 2032	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	>A> 5712279	Feb 21, 2020	DS DP	U-1317		
	>A> 9265758	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	>A> 5712279	Feb 21, 2020	DS DP	U-1317		
	>A> 9265758	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	>A> 5712279	Feb 21, 2020	DS DP	U-1317		
	>A> 9265758	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	>A> 5712279	Feb 21, 2020	DS DP	U-1317		
	>A> 9265758	Mar 07, 2025		U-1316		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	>A> 5712279	Feb 21, 2020	DS DP U-1317			
	>A> 9265758	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	>A> 5712279	Feb 21, 2020	DS DP U-1317			
	>A> 9265758	Mar 07, 2025	U-1316			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	9199977	Sep 06, 2033	DS DP			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	>A> 9265762	May 29, 2027	DP U-1820			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	>A> 9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	>A> 9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	>A> 7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	>A> 7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	>A> 7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	>A> 7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	>A> 7326708	Nov 24, 2026	DS DP U-1227			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	>A> 9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	>A> 9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	>A> 9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	>A> 9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	>A> 9248229	Mar 12, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	>A> 9205082	Dec 22, 2018	DP U-1556			
	>A> 9283216	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	>A> 9205082	Dec 22, 2018	DP U-1556			
	>A> 9283216	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	>A> 9205082	Dec 22, 2018	DP U-1556			
	>A> 9283216	May 10, 2022	DP U-1819			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	>A> 5900424	May 04, 2016	DS U-864			
	>A> 5900424	May 04, 2016	DS U-1817			
	>A> 6428810	Nov 03, 2019	DP U-864			
	>A> 6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	>A> 5900424	May 04, 2016	DS U-864			
	>A> 5900424	May 04, 2016	DS U-1817			
	>A> 6428810	Nov 03, 2019	DP U-864			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	>A> 6489346	Jul 15, 2016	DP U-588		Y	
	>A> 6645988	Jul 15, 2016	DP		Y	
	>A> 6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	>A> RE45198	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	>A> 6489346	Jul 15, 2016	DP U-623		Y	
	>A> 6489346	Jul 15, 2016	DP U-624		Y	
	>A> 6645988	Jul 15, 2016	DP		Y	
	>A> 6699885	Jul 15, 2016	U-623		Y	
	>A> 6699885	Jul 15, 2016	U-624		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	>A> RE45198	Jul 15, 2016	U-623			
	>A> RE45198	Jul 15, 2016	U-624			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	>A> 7399772	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	>A> 7456168	Jan 16, 2023	U-1658		>A> I-725	Feb 19, 2019
	>A> 7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	>A> 7456168	Jan 16, 2023	U-1658		>A> I-725	Feb 19, 2019
	>A> 7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	>A> 7456168	Jan 16, 2023	U-1658		>A> I-725	Feb 19, 2019
	>A> 7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	>A> 9066980	Jan 30, 2024	DP U-528			
	>A> 9066980*PED	Jul 30, 2024				
	>A> 9125905	Jan 30, 2024	DP			
	>A> 9125905*PED	Jul 30, 2024				
	>A> 9173942	Jan 30, 2024	DP			
	>A> 9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	>A> 9173942	Jan 30, 2024	DP			
	>A> 9173942*PED	Jul 30, 2024				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	>A> 7157456	Dec 11, 2020	DS DP U-1301			
	>A> 7157456	Dec 11, 2020	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	>A> 7157456	Dec 11, 2020	DS DP U-1301			
	>A> 7157456	Dec 11, 2020	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	>A> 7157456	Dec 11, 2020	DS DP U-1301			
	>A> 7157456	Dec 11, 2020	DS DP U-1302			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	>A> 6858618	Dec 17, 2021	U-618			
	>A> 6858618	Dec 17, 2021	U-1032			
	>A> 6858618	Dec 17, 2021	U-1807			
	>A> 6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	>A> 6858618	Dec 17, 2021	U-618			
	>A> 6858618	Dec 17, 2021	U-1032			
	>A> 6858618	Dec 17, 2021	U-1807			
	>A> 6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	>A> 6858618	Dec 17, 2021	U-618			
	>A> 6858618	Dec 17, 2021	U-1032			
	>A> 6858618	Dec 17, 2021	U-1807			
	>A> 6858618*PED	Jun 17, 2022				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001					>A> M-171	Feb 26, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	>A> 7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	>A> 7326708	Nov 24, 2026	DS DP U-802			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	>A> 7326708	Nov 24, 2026	DS DP U-802			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795			
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278 001	>A> 9272137	Sep 07, 2027	DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	>A> 6715485	Mar 03, 2020	DP			
	>A> 7975690	Aug 18, 2025	DP U-1809			
	>A> 8047202	Jul 02, 2023	DP			
	>A> 8327844	Oct 03, 2023	U-1809			
	>A> 8550073	Oct 22, 2029	DP			
	>A> 8555877	Mar 03, 2020	DP			
	>A> 8590530	Sep 15, 2025	DP U-1809			
	>A> 8875704	Apr 07, 2028	DP U-1809			
	>A> 8899229	Aug 18, 2030	DP			
	>A> 8978647	Dec 06, 2030	DP			
	>A> 9108015	Sep 15, 2025	DP			
	>A> 9119932	Apr 23, 2024	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001 >A>	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001 >A>	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001 >A>	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002 >A>	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003 >A>	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001					>A> NCE	Nov 06, 2017
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					M-170	Nov 20, 2018
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001 >A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
					>A> D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002 >A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
					>A> D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003 >A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
					>A> D-157	Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004 >A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
					>A> D-157	Jan 28, 2019
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001 >A>	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					>A> M-172	Feb 24, 2019
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					>A> ODE	Dec 11, 2022
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>